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A molecular genetics approach to gene discovery of Mendelian
diseases on the island of Newfoundland
discovery. Newfoundland out-port communities were founded by English Protestant or
The main objective of this thesis was to identify novel disease-causing genesinvolvedin
arrhythmogenic right ventricularcardiomyopathy/dysplasiatype 5 (ARVCID},deafness
myocardium. The causal gene for one subtype ofARVC,ARVD5,was identifiedby
studying IS Newfoundland ARYC families. Haplotype analysis initially revealeda2.36
Mb critical region that all affected individuals shared and after screening positional
candidate genes, a missense variant, transmembranreprotein 43(TMEM43)c.I073C>T,
A large, extended Newfoundland family with non-syndromichearing losswassuspected
regiononXp.Onekeyindividual,whoseparentswerebothaffectedandrelated,hada
Screening a cohort of96 Newfoundland breast cancer probands, withafamilyhistoryof
A critical region on the X chromosome has been identified that segregates with non-
syndromicdeafness ina large Newfoundland family. Despite great efforts, the causal
gene hasnol yet been identified and thus there still remains an oppon.unity fora novel
Theewfoundlandpopulationalsoprovidesanopportunitytoidentifyanovelgene(s) in
breast cancer. Studying the unsolved families (approximately 84% of the BRCAI and
BRCA2 screened cohort) and determining which ones originate from the same fishing
communities may represent clusters of related families that could be used to search for
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Chapter 1: Generalintroduction
1.1 Aimsnftbisstudy
The ultimate goal of this thesis was to identify disease genes lhat segregated in
studied. This general introduction discusses the modem scope of genetics, familial gene
discovery approaches. and the benefits of using founder populations forgenediscovery
Each chapter that follows is dedicated toone of the three slUdied diseases where the
c1inicaJ and genetic characteristics are described more specifically
1.2 Wbymakegenediscnveryeffnrts?
Identifying disease genes improves disease management at many leve!s.1mmediate
impacts include the improvement of disease diagnosis and riskassessment.Asimple
genetic test can provide a diagnosis of disease, which can bebeneficialespeciallyfor
diseases where early diagnosis is critical and can improve prognosis,such as in the case
of cardiomyopathies (1). The risk of disease onset can also be better assessed by
identifying mutation carriers, who, once identified, can be closely monitoredforearly
detection, or maybe even prevention in the future (2). Hamilton discusses the different
preventative measures, including surveillance and prophylactic surgeriesthatpositive
BRCA(breastcancersusceptibilitygene)mutationcarriers,whoareatahigherrisk of
The complete molecular mechanisms that underlie human disease are poorly understood,
butnewinsightscanbederivedfromidentifyingdiseasegenes(3).Suchdiscoverieshelp
elucidatethecellularpathwaysresponsiblefordiseaseandmayprovidenewknowledge
for drug therapies (3·5). A recent review about calcium deregulation inamyotlOphic
(6). Nearly a decade has passed since the first draft of the human genome was sequenced
(7-9). This ground.breaking research has provided a blueprint for the study of
transcriptomics (transcriptional regulation). proteomics (biological function of gene
products) and interactomics (the interaction of proteins). all of which arecrucialinorder
A question that has been posed since the human genome sequence became publica!ly
available is "how many genes are in the human genome?" According to the mostrecent
assembly of the human genome(GRCh37-February2009)andGenebuildby Ensembl
8,483 RNA genes and 12.599 pseudogenes that have been annotated with a total of
148,792 transcripts. The answer to the above question. however. has been suggested to
largely depend on how one defines the word "gene" (10). Gersteinetal.publisheda
comprehensive review discussing the evolution of the definition ofa gene, which
a distinct unit of heredity (II). Later. in the I940s, it was tenned as a blueprintfora
protein, but as the years passed (between the 1960sand I980s) and RNA genes were
recognized,itwasdefinedasatranscriptthatgivesrisetoafunctionalproduct(1I)
More recently, a gene has been described as a DNA segment that contributes to a
particular function or phenotype wh..ich. in the absence of known function, can be
characterized by sequence, transcription or homology (gene annotation) (II). The
genome is however a complex entity. Some genes overlap each other either on the same
completelyindependentbutarewithinanintronofanoverlappinggene(13).Other
genesundergoahematesplicingand,forexample,haveanumberofdifferent first exons
andpromoters(14),and/orhavetissue·specificisofonns(l4,IS). More uncommon are
bicistronic genes, where two genes in cis are tcanscribed together from a single
lranscription site but are later cleaved and processed as ditTerent proteins (16). Thereis
one transcript, which is tenned trans-splicing (17). Defining and categorizing such
transcriplSas multiple genesora single gene is debatable. Furthennore,consideringcis-
acting regulatory elements, should they be included in the boundary 0 fa gene? What if
when screening candidate disease genes one has to lake all this infonnation into
The mutome isdefmed as the specuum of mutations that underlie or are associated with
disease (l8). Over 100,000 gennIine mutalionsthat either cause or are associated with a
new gene mutations and 300 new uinherited disease genes" are being identified (10,18)
genome issuuctured into general haplotypes that are divided into blocks and,within
those blocks,genetic variants are in linkage disequilibrium (19),associationsrudies
became a popular method to study complex diseases (4). Common, low-risk variants that
confer only a small risk of disease were aimed to be identified (20, 21). Thereisadebate
24), and whether multiple common or rare variants actually contribute to complex
understanding of disease it is still very important to identify variants that cause
monogenic traits. Furthermore, a single disease variant that is rare,infersahighriskfor
disease, and segregates within families can be readily identifiedbytraditionalapproaches
I.S Gene discovery efJorts of monogenic traits-a systematic approach
using families
Family studies have been used eff'ectively to identify disease genes over the last 20 years
(4). The resulting discoveries have mainly revealed deleterious variants that affect the
protein sequence directly and increase disease risk substantially. According to Online

statusanddetenniningitsmodeofinheritanceisnotalwaysaneasytask.Complications
defining the disease phenotype and identifying affected individuals. Essentialtremor
(ET) [MIM #190300],a common neurological disorder, is such a disease (28). ETis
characterizedbyposruraltremor(whenapatienlvoluntarilyattemptstomaintainasteady
posture) that subsequently worsens with movement and affects mainly the upper limbs
and,lesscommonly,the head, voice, face, tongue, trunk and lower limbs. The clinical
variability of the phenotype however makes its diagnosis difficuh. In fact. there are no
validated diagnostic tests for ET and the lack of consensus on clinical diagnostic criteria
has resulted in 30-50% of patients previously diagnosed with ETto be misdiagnosed(28)
Recognizing this complication,ET is generally diagnosed as either "definile,""probable,"
or "possible." Despite being a hereditary disorder in 50·70% of patients, studyingET
families has not yet led to the identification ofacausative gene (29),whichcanbe
attributed to misdiagnosis. If an individual from an ETfamily is diagnosedas"possibly"
afTected,but is truly unaffected, classifying that individualasaffected for the genetic
analysis will hinder any gene discovery efforts
Penetranceofaphenotype.givenapacticulargenotype,isdefmedastheprobabilitythata
person who has the genotype will manifest the phenotype. Jfanalleleishighly(IOOO/o)
penetrant, as is the c.338T>C mutation in connexin 43 [MlM #121014],whichcauses
autosomal dominant, congenital,oculodentodigital dysplasia [MIM #164200] (30),the
Penetrance is said to be reduced or incomplete when some individuals fail to express the
trait. even though they cany a mutant allele. Regarding autosomal dominant inherited
traits, if a mutation camer is asymptomatic but has an affected child the mode of
inheritance maybe mistaken as recessive. There are examples of hereditary breast cancer
families with high risk breost cancer susceplibi/itygene I or2(BRCA/[MIM#113705]
orBRCA2[M1M#600185])mutationswherecarriersneverpresentthediseasephenotype
(31,32). By 70 years of age, breast cancer penetrance forBRCAl and BRCA2 mutation
Penetrance can also be age-related. Thepenetrance of highly penetrantBRCAland
BRCA2allelesareagoodexampleofthisaswell(31,32).lthasbeenshownthat
differentBRCAlmutationsresultindifferenlmedianagesofonset(32).For example,
c.185de1AG in exon2 has a median age of onset of 55 years, compared to variants with a
higherpenetrance,c.4184deITCAAinexon II andanexon 13 duplication, where the
median ages ofonsel are 47 and41,respeetively(32)
Lowpenetrance alleles also exist, which are alleles that have a low associatedriskof
developing the disease. For example, 12 Ataxia-teJangiectasia mutated (ATM) [MIM
#607585] mutations were identified in breast cancer patients after studying 443 familial
breast cancer pedigrees. Women with these variants were detennined to have an
1.5.2 Systematic approacb-Part 2 (genetic analysis of families)
Before the search for a new gene commences, known disease genes and/or loci are
generally excluded as the cause of disease. This is common when studying genetically
heterogeneous diseases and will save time, effort and money if the family can be solved
using this approach. However, when a disease has many known causatives genes, such as
deafness (38),it is sometimes more effective to skip the exclusion process or screen for
only the most commonly mutated genes. Autosomal dominant cerebellarataxias are a
clinically and geneticsllyheterogeneous groupofneurodegenerativedisorders
characterizedbyimbalance,progressivegaitandlimbataxia,anddysarthria(39,40)
Thefirstgene,SCAI(responsibleforspinocerebellaratsxistypel)wasidentifiedinl993
(41). At present, st least 25 distinct genetic fonnsofSCA are known, and many are
caused by tri-nucleotide repeat expansion mutations within the coding regionofthe
corresponding genes (42). Jn2006,SCA28wasanovellocusidentifiedonchromosome
18p11.22-q11.2 by studying a four generation Italian family. Before the searchforthe
novel locus commenced, genetic analysis excluded the presence of repeal expansionsin
the SCA genes associated with those types of mutations, and linkage analysis was
performed to exclude the remaining known loci (40)
Novelgenediscoveryapproachesin/amilies-Candidategeneandgenomescan
approach
Two research approaches have been commonly used to identify monogenic disease genes
when studying disease families, the candidate gene approach and the genomic screening
Forthecandidategeneapproach,genes are selected based on their known orpredicted
biological function and/or on their relation to the disease. Forexample,hereditary
sensory and autonomic neuropathy type 4 (HSAN4) [MIM#256800] isaveryrare
autosomal recessive disorder that involves both pain insensitivity and autonomicdefects,
which is described as a congenital insensitivity to pain with anhidrosis(inabilityto
perspire) (43,44). In 1996 Indo etal.screened 3 candidate genes (NTRKJ,NGFandp75
neurotrophinreceptor) in three unrelated HSAN4 patients, all of whomhad
consanguineous parents, based on similar phenotypes that were reported in the knock-out
mouse models for these genes (45). No mutations inNGForp75 neurotrophin receptor
wereidentified,howeverthreedifferentNTRKl [MIM #191315] variants (a deletion,
splice mutation, and missense mutation) were detected which suggestedNTRKlwasthe
pathogenic HSAN4 gene (45) Since that time over 40 different HSAN4 NTRKJ
Database:hun:ll .hgmd.cf.ac.uklaclgene.nhn?gene=NTRKI)

whichisappropriateformorecomplextraitswheretheexactgeneticmodelis hard to
define. The basic concept behind a nonparametric linkage analysis is to identifymarkers
where the same identical-by-decent(IBD) allele is shared berween a£fected individuals-
berween all sib-pairs in a pedigree. for example (50)
Parametric linkage has been a very successful and common approach for mapping
observing a phenotype in a family due to genetic linkageberween loci. where the
likelihood ofobserving a phenotype in a family assuming there is no linkage berween Ioci
of linkage compared to no linkage. The logarithm of the odds ratio is the LOD score (Z)
LODscores area function of9,thus lheyare calculated for a rangeof9 valuesforeach
marker. The 9 value with the highest LOD score is the most likelyrecombination
fraction. A rwo-point linkage analysis is the simplest calculation and involves
independently calculating LOD scores for each typed marker and thedisease locus. The
threshold for accepting linkage is a LOD score of3, which corresponds to an odds ratio of
1000:1 for linkage (1og (1000) = 3). Similarly, linkage can be rejected whentheLOD
score is less than or equal to-2. Regarding the SCA example that was mentionedabove,
after all known loci were excluded a genome wide scan was carried out on the Italian
family and linkage was identified with markers on chromosome IS. A maximum rwo-
point LODscoreof4.20 (9=0) was observed for markerDJ8S53 (40). A multi-point
linkage analysis can also be carried out which takes into consideration the framework of
the disease locus and its boundaries The minimal region thaI is shared by all affCCled
DNA sequence of the disease region by downloading it from theworld-wide-web using
52). Before this luxury existed a eontigofgenomie clones had to be established aeross
the candidate region, whieh is a groupofgenomie elonesthat overlap with eachotherand
together represent the original sequence of the chromosome segment. This was the
techniqueusedbytheHumanGenomeProjecttoestablishthefmmeworkforsequeneing
Genes within the disease-linked region are called positional candidates and ean be
identified using genome browser databases as well (52). ThisispossibIe because another
goal of the Human Genome Project was to construct the human gene map (7,8),thusthe
disease-linked region and all annotated positional candidates can be graphically displayed
on these sites making it extremely easy to identify candidate genes . The 7.9 Mbinterval
segregatingwithSCAintheltalianfamilycontainedover30genes(Build36 version 2)
(40).ltisimportanttonotethatthelistofhumangenesandisofonnsisincomplete,so

More recently large genomic deletions and duplications have been recognized as disease
causing. The mechanism that causes many of these rearrangements is nonallelic
homologous recombination or unequal crossovers of chromosomes between low-copy
repeats (LCRs) (also known as segmental duplications) (57). A single exon. aseriesof
exons, a whole gene, or even large chunks of DNA ranging from tens of thousands to
millions of base pairs can be deleted or duplicated (these variants are known as copy
number variants orCNVs),all of which have a Mendelian pattem of inheritance. One
relatively new technique that enables the identification ofexonic duplicationsand
deletions is multiplex ligation-dependent probe amplification (MLPA) (58). The
detection of such rearrangements has solved several families that were previouslylinked
deletionslduplications have been found in genes that cause hereditary colon (59, 60) and
breastcancer(61,62).lnfact,atleast81difTerentBRCAlgenomicrearrangementsand
17 BRCA2 genomic rearrangements have been reported to date (63), and studies carried
out mainly in Caucasian populations have shown that 4-28%ofBRCA mutations maybe
genomic rearrangements (64). There have also been at least 20 difTerent humandiseases
described that are caused by deletions of cis-acting regulatoryelements(65).Halfofthe
mutations in thePOU~domainc/ass3 transcription factor 4 (POU3F4) [MLM #300039]
gene that cause deafness are deletions ofa regulatory element (66). Inmostcases,
deletions of regulatory elements are not as common as deletions in the openreading
frame but that could be due to screening biases (65,67),hencethe proportionof
pathogenie rearrangements that playa role in genetiedisorders is likely underestimated
(2eJ Mutation validation o!variantsdetected in positionalcandldategenes
Generally, a small number of affected family members and unaffeeted eontrols are
found in affected individuals are highlighted. The next step in the exclusion processis
detennining which of these variants segregate on the diseasehaplotype,foJlowed by the
screening of the segregating variants in population controls to detennine allele frequeney.
Rarevariantsaremorelikelytobepathogenic,andarethusfurtheranalyzed.Perfonning
additional bioinfonnatic analyses can help to predict the effect a variant has on RNA
splieingandproteinfunetion.lfavariantisinacodingregionitismorelikelytobe
pathogenic if an amino acid is highly conserved in orthologs, thusconservation analysis is
also useful (68·70). Another helpful clue is if the variant is in a gene whoseprotein
product has a similar function or is in the same signaling pathway as the encodedproteins
ofothercausalgeneswhosemutationscausethesamedisease.Ultimately, the most ideal
validationmethodsincJudeidentifyingadditionalfamiliesthathaveamutation(s) in the
same gene, and performing functional studies in order to show pathogenicity
AFG3L2,whichencodesamitochondriai metalloprotease (ATPase family gene 3-like 2)
was presumed to be the SCA28 mutant gene after mutation screening and detecting
differentheterozygousSCA28mutationsinfivedifferentSCA28families.Forvalidation,
in yeast resulted in a defective activity of cytochrome c oKidase (COX) and impainnentof
cell respiration (55). Di Bellaet al. also noted that AFG3L2 is highly and predominantly
expressed in cerebellarPurkinje cells, which is consistent with the pathological phenotype
1.6 Geoediscoveryioisolatedpopulatioos
Gene discovery efforts have been very successful in isolated populations, which are
groups of people who have been restricted from intennarriagewith other groups due to
ditTerencesinculture,religion,language,geographyorotherfactors(71).Generally
these populations descend from a limited number of common ancestors; this can aIso
define the group as a founder population. These populations are morehomogeneousthan
out bred populations thus the majority of individuals with a disease will often carry the
1.6.1 Exampleofa founder population and global medical benefits
There are several examples of founder populations around the world that have been used
to study genetic diseases. The French·Canadianpopulation is one prominentexample.1t
isafounderpopulationthatexceeds7millionpeople,6millionofwhomareof French
decent (72. 73). The Canadian province of Quebec was founded by French immigrants
whosenledalongtheSt.LawrenceRiverintheearlyI600s.1n1608,immigrantsftrSt
settled in what is today Quebec City. Immigration continued along the St. Lawrence
Riveruntil1759,whenEngiishsettierstookovertheiandandhaitedFrenchimmigration
Atotalof8500Frenchimmigrantshadsettledpermanently;however,bythelatel600s
naturai expansion had exceeded immigration (72, 74),such that by 1759,76,000 French
Canadians lived in settlements along the river (73). Both language and religion restricted
marriages with the newly arrived English speaking Protestants (French Canadians are
almostexclusivelyRomanCatholic).lnfact,inordertopreservetheirculture,French-
Canadians were encouraged to have large families, known in Quebec as "the revenge of
the cradles." This led to several founder effects that were specific to difTerent rtgionsof
the province since most settlements along the river were geographically isolated (n).
Despite inter-regional mixing, urbanization and decreased birth rates in the 20th century,
Many genetic diseases have been recognized in the Quebec population (73),forexample
autosomal recessive spastic ataxia ofCharievoix-Saguenay (ARSACS) [M£M #270550]
ARSACS was reported initially in the province (75),and the causative gene was
identified by studying the Quebec population (76,77). When the genetics ofARSACS
was firststudied,300 patients were identified,all of whom originated fromthe
Charlevoix-Saguenay region of northeastern Quebec. A genome-wide scan was
performed on 12 families and excess shared homozygosity was observed at 13ql I.
Additional analysis on 19 families suggested two ditTerent ARSACS haplorypesexisted
in this region (77),and as a result two Freneh Canadian founder mutations intheSACS
gene[MlM#604490l,e.6594deITande.5254c>T,havenowbeenidentified(76).Sinee
then, mutations in SACS have been recognized as causing the same eondition inother
populations around the world. SACS mutations have been found in Tunisian,Italian,
Spanish,Japanese, Turkish and Dutch patients (78-85). This example demonstrateshow
Quebec gene discovery efforts pennitthe molecular diagnosis for patients outsidethe
founder population, and illustrates the global benefits of studying isolated populations.
1.6.2 Newfoundlaod as a genetic isolate
Newfoundland,part of the Canadian province Newfoundland and Labrador, is an island
ofT the country's east coast. It has many distinct genetic isolates, particularlyalongits
coastline in out-port eommunities that were fLfStestablished as fishingcommunities (86).
Newfoundlandisrecognizedasbeingfirstdiscoveredinl497byanltaliannavigator,
JohnCabot,andseasonalimmigrantsfirstsenledintheearlyI600s. Pennanent
immigration did not occur, however, until the mid l700s, which rnainly included English
Protestants from south-west England and Irish Catholics from south-east Ireland (86)
expansionto200,OOObytheIatel800s. Today there are approximately 500,000
residents, 98% of whom are of English or Irish descent, and 60% of whom live in
communities of less than 2500 residents (87-89). Geographical distance between
communities and religious segregation are the two main factors that have contributedto
the development of several Newfoundland isolates (87)
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2.1.2 Natural history of ARVC
2.1.3 DiagnosisofARVe
lnitial reports on ARVC conc!uded that it was a rare, severe disorder and all patientshad
a dilated right ventricle and sustained VT(113),thus milder cases or more severe cases
thatcauseddeathbefore'presenting'thediseasewereoverlookedormisdiagnosed
Since then, additional fearureshavebeenrecognized,forexamplethe importance of
histopathology for diagnosis in order to detcct the fibro-fanyreplacememofthe
myocardium,andthefrequentinvolvementofbothventricles(l22·125).lnl994,aset of
International Task Force diagnostic criteria forARVC was created that included six
different classes with major and minor criteria (126). For diagnosis, an individual has to
fulfill either two major, one major plus two minor, or four minor criteria (126). These
criteriahavesincebeenmodified(127)inordertorecognizeasaffccted,forexample,less
severelyaffccted family members of known ARVC families, who did not fulfill the Task
Force criteria (127). Current limitations of the Task Force criteria still include not
recognizing deceased relatives as affected,even when an autopsysuggestsARVC,which
is detrimental when an extended family history is available and SCD isa primary
presenting feature. Also, the level of clinical testing needed fora Task Force clinical
diagnosisisonlyofferedattertiarycenters(hospitalsthatofTerafuII complement of
services),thus some cases are unrecognized and perhaps misdiagnosed only because the
ARVChasbeenreportedworldwide(128·131),however, its exact prevalence and
manyARVCstudies(132·135),andafterconductingpostJnortemstudieson60
individuals under 35 years of age who had died suddenly innorth--eastem Italyfroml979
(123). A group in the USA studied sudden unexpected nontraumatic deaths between
1960 to 1989 in a young adult population (aged 20 to 40 years old) from Minnesota,and
suggested that 17%ofSCDs in those young individuals were a result ofARVC (136).
Another study in France perfonned a retrospective analysis of 1700 forensicautops ies
following unexpected sudden cardiac death that occurred between 1981 and 1997,and
revealed a group of 50 cases where death occurred during surgery/anesthesia
authors suggested that 18 of the 50 cases (36%) wereARVC-related (137)
ARVC is recognized as a heritable disorder with, typically, an autosomal dominant
pattern of inheritance. It is genetically heterogeneous with 12 known autosomal
dominant loci (ARVDl-12). One recessive syndromic fonn ofARVC (Naxosdisease)
[MLM#601214]exists(Table2.1). In fact, the gene for Naxos disease was the first
2.1.6 Autosomal recessive syndromic ARVC
Mutations inplakog/ob;n (gammacatenin) (JUP) [MIM#173325] cause a recessive
syndromic forntofARVC called Naxos disease (I38). This syndrome involves a triad 0 f
woolyhair,askindisorderknownaspalmoplantarkeratodenna,andARVC,andwasftrst
clinically reponed in 1986(139). Naxos disease was mapped 10 chromosome 17, in
1998, by srudying nine Greek families with 21 affected individuals (140),and in 2000,
McKoy et al. identified a homozygous 2 bpdeletion in the C-tenninU50fplakoglobin.
PlakogJobinfunctionsincellassemblyinboththedesmosomeandadherensbutitaJso
has a role in gene regulation in the WNT (wingless type) signaling palhway. Plakog/obin
mutations, therefore, possibly disturb proper cell-cell adhesion andloTa criticalsignaling
TheARVDllocus,locatedatI4q23-q24,wasmappedinI994bystudyingtwolarge
obtained at marker D14S42 after a genome·wide scan (133). In 2003, two additional
families (one Italian and the other German) were detennined through linkage exc1usionto
have distincthaplotypes that segregated with ARVC at the ARVDJ locus. Maximum
LOD scores (at 9=0) of4.4l with marker D14S254 and 4.06 with marker D14S983 were
obtained for the Italian family. However,fortheGennanfamily,amaximumLOo score
of 1.51 (9=0) was obtained for marker D14S59, which the author suggested was due to
the small family size (141). ln2005,mutation screening of the regulatory 5' UTRof
TGFP-3 in one of the Italian families described above, identified a variant (c.l-36G>A)
thatsegregatedwiththedisease(14I,142).Screening30additionaIARVCprobandsfor
TGFP-3 variants identified another variant (c.l723C>1) in a single proband. Neither
nucleotidechangewasfoundin300controlsubjects(l42).TGFp-3mutationshave not
been reported for the other ARVDJ-linked families
(il)ARVD2[MIM#600996]
The second ARVO locus was mapped to Iq42..q43 by studying a nonh-eastem Italian
family (l34). A LOD sc:ore of 4.02 (9=O),assuminga 95%penetrance, was obtained
using a CA-repeat polymorphism within the gene acaninalpha-2 (ACTN2) [MIM
#102573]. The family also showed significantly positive LOO scores for markers
flankingtheACTN2gene(134).ln2001,thelocuswasrefinedandthecausativegene
identified after studying four Italian families, including the familyused to originally map
ARVD2,which had been clinically updated ina later report (143,144). Aftersc:reening
ryanodine receptor 2 (RYR2) [MIM. #180902], which encodes a calciumchannel,four
missensevariantsp.RI76Q,p.L433P,p.N23861 and p.T2504M were identified, all of
which were located in highly conserved regions of the protein and criticalforthe
(iii)ARVD3[MIM#602086]
ARVD3was identified by studying three unrelated families with ARVC from Italy,
Slovenia, and Belgium (132). ARVC in all three families linked to the chromosome
region 14q12..q22 with a cumulative two-point LODscoreof3.26 forDJ4S252 (9=0) and
a multipoint rnaximal cumulative LOD scoreof4.7 between loci DI4S251 and DI4S257
(132). This)ocus was provisionally named ARYDl in the original manuscript however it
has since been calledARVD3. The manuscript describing the discovery of the current
ARVDl IOCllS (134) had been accepted but not published in thejoumal HumanMolecular
Genetics when theARVD3 discovery manuscript was first submined to Genomics (132)
(iv)ARVD4[MIM#602087]
ThediscoveryofARVD4involvedalinkageanalysisonthreefamilies(J35).Twoof
those families were Italian, and one was American with European ancestry, and was
previollslydescribedin1993(145).AlIthreeARVCfamilieswerecharacterizedby
loci. Therefore.Rampazzoetal.suspectedfurthergeneticheterogeneityandperfonneda
two·point linkage analysis to identify the fourthARVC locus (135). The disease
appeared to be transmitted with three polymorphic markers (D2SJ52. D2SI03. and
D2S389) on 2q32.1-q32.3. A maximum LOD score of3.46 (EFO) for the marker D2S152
was obtained (135). The causative gene remains to be identified
(v)ARVD5[MIM#604400]
TheARVD5locuswasmappedinanex:tendedsevengenerationfamilyfromthe
genetically isolated population of Newfoundland (146). This family was frrstidentified
intheI980s(l47).Therewere200individualsinthislargefamily,includingIOliving
hadanautopsyandallhadfat-fibroreplacement.Atwo-pointlinkageanalysiswas
perfonned,assumingan autosomal dominant inheritance and a penetrance of 200/0. 6QO/o,
80010 and 95% for individuals under the age of 15, between 15 and 35 years of age.
between 35 and 55 years of age, and over 55 years of age, respectively. Only onelocus
LODscoreof6.9Iwithzerorecombination.Haplorypeanalysisidentifiedashared
region of 9.3 eM between markers D383610 and D3S3659
(vi)ARVD6[MIM#604401]
TheARVD610cuswas identified ina large Caucasian North American familywitha
highlypenetrant,early-onsetARVC(148). The first five known ARVD loci were
initially excluded lhrough linkage studies, thus a genome scan identified a novel locus on
chromosome IOpI4-pI2. A maximum 2~point LOD score of 3.92 (6=0) was obtained
with marker DIOSI664. A 1O.6cM shared hap!otype was generated between markers
DIOS547 and DIOSl653 (148). A second family with ARVD6 was identified in 2006 and
was used to narrow the critical region to 2.9 Mb (149). This family was of South African
descenl.Theexonicregionsoftwopositionalcandidategenesthatwereinvolved in cell-
cell adhesion (1TG8and FRMD4A) were screened but no causative mutations were
detected (t49). Thus, the ARVD6 gene has yet to be identified
ARVD7 is also known as myofibrillarmyopathy (MFM) with ARVC. This locus was
identified in a Swedish family whose affected individuals suffered fromamyopathy
(morphological changes in the skeletal muscle) and ARVC (150). Linkageanalysis
showed a maximum 2-point LOD score of 2.76 (8=0) with marker DIOSI752. and a
multi-point peak LODscore of 3.06 between markers DIOS605andDIOS215. This
disease interval is located at 1Oq22.3 (150). After re-examination in 2008,the critical
positional candidate genes, includingZASP [MlM #605906l,whichwaspreviously
associated with myofibrillarmyopathy (l52),revealed no pathogenic variants (151)
Interestingly, also linked to this critical region is dilsted cardiomyopathy IC(CMDIC)
whose causative gene is LDB3 [MIM #605906] (t53). Kuhleta1.suggestedthatARVD7
andCMDICmaybeallelicdisorders(J51),howeverthecausalgeneforARVD7remains
(viii)ARVD8[MIM#607450]
In 2002. Rampazzo etal. identified an lralian family that was unlinked to the other known
ARVCloci(t54).Afterperfonningagenome-widescanthediseaseappearedtobe
linked to 6p24. Several markers in that region showed posilive linkage and the maximum
2-point LOD score was 4.32 (9=0) for marker D6S309. All affecled individuals shared a
common haplotype between markers D6S/574 and D6S/71/ thai encompassed
approximalely6Mb(154). WithintheARVD8Iocuswasdesmop/akin(DSP)[MlM
#125647],adesmosomal gene, for which C-lerminal mUlationshad been previously
reported to cause a recessively inherited triad syndrome involving dilated leftventricular
cardiomyopathy, wooly hair, and a skin condilion known as generalized striale
keratodenna(154, 155). A missense mUlalion (p.S299R) inexon 7 was idenlifiedthat
segregated with ARVC in the Ilalian family (154); it is in theN-lenninal and it modifies
thepulaliveproteinkinaseC(pKC)phosphorylalionsitethatinteractswithplakoglobin.
Plakophi/in-2(PKP-2) [MIM#602861],anotherdesmosomal gene, is the causal gene in
ARVD9(156).Gerulielal.selectedPKP-2asthecandidalegeneforARVCbecause
Pkp2-nullmicediedatembryonicdaylO.75duetoadefeclincardiacmorphogenesis
(157). Afterscreeningl20westemEuropeprobandswithARVC,25difTerenlmutations
were identified solving 32 cases (156). Another study has reported 14 PKP-2mutations
in24of56 Dutchprobands, II of which were novel (158). The mutations found in both
studies mainly resulted in truncated or aberrant proteinsasa result of deletion/insertion,
nonsense or splice site mutations. Many of the missense mutations changed highly
arethoughttocauseofupto40-700looffamiliaIARVCcases(158,159).
(x)ARVDJO(MIM#610193]andARVDl1(MIM#610476j
After PKP-2 was identified as theARVD9 gene in 2004, it was suggested that ARVC may
associated with the disease, along with DSP(ARVD8) and JUP (Naxos disease) (l56).
Several groups took a candidatc gene approach and screened desmoglein-2 (DSG2)[MIM
NI2567Ijanddesmocollin-2(DSC2)[MlMNI25645j,lWodesmosomalcadherin
proteins. Mutations in both genes are nowsssociared with ARVDIO andARVDJI
The DSG2 gene was ftrstanalyzed in 54 Italian ARVC probandswho screened negative
formut8tions in the TGFp3,DSPand PKP-2 genes. DSG2 mutations were detectedin
eight probands, including five missense mutations, two insertion-deletions, one nonsense
mutation,andonesplicesitemutation,Sevenprobandswereheterozygous and one
proband was compound heterozygous (161). Neithermutationwasdetectedin560
Two manuscripts suggesting that mutations in DSC2 cause ARVC were acceptedfor
publication on the same day (September6,2006). One study screened 77 unrelated
ARVC probands and identified two different DSC2 heterozygous mutations,a deletion
and an insertion, in fourprobandsfrom four unrelated families. Bothmutalionsresulted
in frameshiftsand premature truncation ofthedesmocollin-2 protein (164). Thesecond
study screened 88 unrelated patients withARVC for DSC2 mutations and identifieda
heterozygous splice acceptor site mutation in intron 5. This resulted in the useofa
cryptic splice acceptor site and created a downstream premature termination codon. This
(xi)ARVDJ2 (MIM #611528]
Mutations inplakoglobin (JUp) have been, more recently, determined to also cause a
dominantly inherited non·syndromicform ofARYC,ARVDJ2(166). A novel dominant
mutation inp/akog/obinwas identified in a Gennan family, which is located in the N-
terminus of the protein and inserts an extra serine residue after serine 39(166). ThisN-
resulting in the syndrome Naxos disease. This is similar to mutation effects in
desmoplakin, where mutations in the N-terminus are dominantly inherited and do not
which code fordesmosomal proteins. Thus,ARYC has been considered adisease of the
desmosomes,whichindicatestheimportanceofcelladhesionmoleculesinARYC
pathogenesis (167). Desmosomesaswellasgapjunctionsandadherensjunctionsare
three types of cell-cell connections called intercalated discs. Cardiac cells rely on


(iii) Desmosomal plakin-Desmoplakin
Desmoplakin{DSP) is exclusively found in desmosomes but isubiquitously expressed. It
is the key protein to the inner desmosome. It is responsible fordesmosomal assembly.
stability, regulation and modeling of tissues during embryogenesis (168). TheN-tenninal
domain of desmoplakin binds to the annadillo proteins. and the C-tenninusof
desmoplakin is responsible for anchoring desmin (an intennediate filament in the
sacromere)tothecellsurface(Figure2.l)(l68,169).ADSPmutant(R2834H)mouse
modelwasestablishedandover-expressionofthatproteinledtocardiacbi-ventricular
apoptosis, fibrosis, enlargement and dysfunction. whereas wild-type DSP micehadno
2.1.9 ARVCvariableexpressionandpenetrance
Specific studies anempting to characterize genotype-phenotype correlations have been
carried out in ARVC cohorts and the phenotype has been shoWll to be variable. One
studyprovidedaclinicalevaluationofARVCfamiliesharboringmutationsinPKP-2
(173). The clinical expression ofPKP-2 mutations in affected individuals varied
tremendously, even amongst first-degree relatives, ranging from acompletelackof
symptoms to a severe disease phenotype. Evaluation of the genotyped family memoors
quite widely in these PKP-2 families as well. The age at diagnosis was between 8 to 45
Another study invesrigated thegenotype·phenotype correlation for DSG2 mutationsand
ARYCclinical expression (163). Themeanageatdiagnosisforthcprobandswas 32.6 (a
asymptomatic individuals may develop the disease later in life. Dividing gene positive
individuals into age groups (2Q-40 and >40 years of age) showed higherpenetranceinthe
older group (50 and 75%respectively.forTask Force critcria) (163).
screeningdcsmosomal genes for mutations. The main objective of this work was to
identify theARVD5 disease gene. TheARVD51ocuswaspreviouslymappedinaiargc
Newfoundland family (146). Therefore, positional cloning was used to discover the
2.2.1 Study population
lntemationaITaskForcecriteria(126)wasdifficult. Each fiunily had an cxtcn<ded
tertiary medica! center is not accessible Assucln.the'standard·testin.reOlliredtn
clinically unaffected (defined in Figure 2.6) Atotalof295indivillualsac'rossth,eI5
of participants was extraeted from lymphocytes and stored in the DNA diagnostic lab 0 f
Eastern Health. Recently, blood samples were sent to the research laboratory of Dr
Terry~Lynn Young where genomic DNA was extracted and cell lines established
lnfonnedconsentwasobtainedincompliancewiththeHumanlnvestigationComminee
requirements of the Eastem Health Corporation ofSt. John's, Newfoundland. Canada
2.2.2 DefiningtheARJlD510cus
Family 64 (Figure 2.2) was the family used to map the ARVD5 locus to chromosome 3p
(146). Only one marker with a LOD score over I.S was identified, D3S3613 (a peak 2~
point LOD score of6.9l (6=0». Ahmad et al. built a thirteen marker haplotype (Table
2.2) using 10 living affected individuals and two deceased individuals,whosehaplotypes
were inferred from their children (146). A telomeric recombination between D3S3610
a 9.93 Mbdisease region between markers D3S36/0-D3S3659 (Table 2.2) (146)
TheARVD5 haplotype was recapitulated in the Young lab (17S) by firstgenotyping
genomic DNA from individuals in Family 64 using 18 microsatellite markers(including
markersintheoriginalmarkerset)(Table2.2)andmanuaJlyreconstructinghaplolypes
(Figure2.7A). Similarly. genomic DNA from all available family members of the 14
additional families was genotyped and the same disease-associated haplotype was
detennined to also segregate with ARVC in those families. The shared haplotype
betweenfamilieswaspresumedtobeancestral(Figure2.7A).lntheoriginalmapping
paper,D3S36/0wasthetelomericboundarymarker(146).lntheYounglab,the
confinned in families 76 and 453 (Figure 2.3 and 2.4) where all individuals with the
ARVD5haplotypehadtheallele'256'insteadof'246'(Figure2.7A). Another
recombinant haplotype was identified in family 840 (Figure 2.4) where all individuaIs
withtheARVD5haplotypehadalle1e'351'insteadof'347'atmarkerD3SI5/6(Figure
2.7A).However,itwascautiouslydecidedtoonlynarrowtheregionifrecombinations
recombination reduced the critical region to 2.36 Mb from 9.93 Mb between markers
2.2.3 Screening positional candidateARVD5genes
The contig of the 2.36 Mbcritical region was detennined using the UCSC Genome
Browser homepage (http://genome.ucsc.edu/index.hlml?org=Human), and the March
2006 assembly (Build 36.1). In search for the ARVD5 gene, all annotated genes in the
critical region from Refseq were noted (Figure 2.7B and Table 2.3) and screened

first trial then the annealing temperature was increased and/or the final MgCI2
specific/stringent. lfmoreor less MgChwas added to the PCR mix then the H20 volume
wasadjustedaccordingsothatthefmaivolumeofthelXPCRmixwasstill25jJI.lfall
else failed,anadditional primer set was ordered. The conditions for all the primer sets
used during this project are listed in Appendix 3
The PCRproducts were purified using 50%sephacryl (Amersham Biosciences)and
MultiScreenHTSfiherplates(MiIliporeCorporation). PurifiedPCRproductswerecycle
sequenced in both the forward and reversedircctions with the useofa BigDyeTenninator
V3.lcyclesequencingkitonanautomatedABI3700DNAanalyzer.Thesequencing
reactionhadafinalvolumeof201JIandll16oftherecommendedvolumeofsequencing
mix was used. AsinglereactioncontainedO.SlJlofsequencingmix,21JlofSX
Sequencing BufTer, I IJlofpurified PCRproduct, 2 IJlofeitherthe forward 0 rreverse
primer(1.6IJM)and 14.51JIofH20. The cycle sequencing PCRhad 25 cycles. Each
cycieinvolveda96°C-IOseconddenaturingperiod,SO°C-Ssecondannealingperiod,
Aftercycie sequencing, 5 IJI of 125 mM EDTA and 65 IJI 95% ethanol were added t0
each sample. The samples were then precipitated overnight, in darkness, preferablyat
4°C. After precipitation, the samples were centrifuged at 3000 g for 30 minutestopellet
the DNA. The plate was then inverted and placed in the centrifuge forapproximately20

amplified on one plate. This panel was screened for all primer sets (Appendix 3) under
the optimal conditions that were detennined from the above PCR trials.
Priority screening of the positional candidate genes was based on gene function,
expression, and information given to the Young laboratory from Dr. LudwigThierfelder
in Gennany, who previouslyanempted positional gene screening. The first gene to be
screenedwasfibuUn.2(FBLN2).FBLNlwasaninterestingcandidatebecauseprevious
screening detected several potential pathogenic variants (data not published,Thierfelder
personal communication), and furthermore, the gene product is involved in organ
development, particularly, the differentiation of heart. skeletal and neuronal structures
The second gene to be screened was WNT7A. The WNT gene family consists of
structurally related genes that encode secreted signaling proteins. Theseproteins are
involved in regulating cell fate and paneming during embryogenesis. Itwasrecently
detenninedthat suppression of the WNT/~-catenin pathwaybyplakoglobin resulted in
theARVCphenotype(171),thusWNT7Awasagoodcandidate. Theremaining
positional candidates were generally chosen based on their size, with the smaller genes
As each positional candidate gene was sequenced all variants were recorded in an excel
database (Appendix 5). This database was created before the mutation screening
commenced,at which time, only the genotypes of each microsatellite markerinthe
ARVD5hapiotype for all seven individuals chosen to be on the mutation screening panel
were included. Each marker in the haplolype was designated to a row in the database
(based on their Mb position on chromosome 3),suchthatthe previouslydetennined
haplotypes (175) were visible vertically in columns. As each new sequencing variant was
identified,wewereabletocontinuebuildingthehaplotypesbyplacingthevariants in the
database (based on its chromosome position) and displaying the corresponding genotypes
for each individual on the screening panel (based on the most likely haplotypes).lfa
assumed to be on theARVD5 haplotype during this stage of the analysis.
2.2.4 SegregatiooAnalysis
Variants that were found exclusively in clinically affected subjects on the mutation
screeningpanelwereofinterest.lnordertoverifyifthesevariantsdidinfact reside on
theARVD5haplotypesegregationanalysisinfamilyl139wascarriedout(Figure2.5)
2.2.5 ARVD5AlleleFrequencies
The allele frequencies oftheARVD5 sequencing variants were detenn inedusing
Newfoundland population-based controls, which were obtained through random digit
phonedialing,aspartofalargecolorectalcancerstudy(177).Sequencing variants that
were detennined to be rare «1% of the control alleles screened) were screenedinaH
were shared amongst all clinically affected individuals
2.2.6 BioinformaticAnalysis
Conservation of the TMEM43 protein across species was determined usingClustalWand
Weblogo(170, 178, 179), and the effects of amino acid substitutions on proteinfWlction
were also predicted (180-184). Potential protein localization, function, stJUcture and post-
tTanslational modification sites were predicted using the online tools via the ExPASy web
2.3.1 Positionalcaodidategenesandmutationscreeoiog
The 2.36 Mbcritical region conrained 20 annotated genes (Figure 2.7B and Table 2.3)
After all 20 genes were screened a total of 240 variants were identified (Appendix 5)
Below the genes are described in the order they appear on the ARVC haplotype (Figure
lQSECJ (IQmotijandSec7domain Jprotein)
IQSECI encodes a protein of unknown function (51). Five non-codingvariants were
found in lQSECI.three within intronsand two within the 3'UTR. Four of these variants
were detected in controls on the screening panel andone.c.65+73C>G,wasdetected in
only one affected individual on the panel. None of these five variantswerefound
exclusively in all affected individuals on the screening panel so they were excluded as the
NUP2JOencodes a membrane-spanning glycoprotein known as a nuc1eoporin protein.
The nucleoporin family of proteins is the main component of the nuclear pore complex,
the structure that acts like a gateway and regulates the flowofmacromoleculesbetween
the nucleus and the cytoplasm (51). Thirty three variants were found in NUP210.
Twentywerenon-coding(fivewerewithinthe3'UTRandISwereintronic)andl3 were
coding. Twenty.eightofthesevariants were found in controls on the screening paneland
fiv•• C.5664+365A>T.C.4582C>T.c.2964+143C>T.C.305-17T>Candc.I66+~;~~Ii
were found in only one affected individual. Again, none of these variants were found
exclusively in all affected individuals on the screening panel so they were excluded as the
and may be involved in regulating the expression ofinterleukin 10(51). There were five
was found in only one affccted individual. Thus, these four variants were excluded
(Appendix 5). There was one variant ofinteresl, c.369+18_369+19insG that was found
exclusively in all theaffccted individuals. This variant was not excluded despiteone
FBLN2 encodes an extracellular matrix protein that belongs to the fibulinfamily. This
protein is known to bind various extracellular ligands and calcium,and it is suspected to
playa role during organ development. More specifically, it may be involved in the
seven were within the 3' UTR),sevenwere coding and six were found in intragenicESTs
(expressed sequence tags) that were screened (Appendix 5). All of these variants were
excluded from further analysis because they were detected in controls 0 n the screening
WNT7A (wingless-type MMTYintegration sitefamily member 7A)
WNl7AispartoftheWNTgenefamily,agroupofstrucrurallyrelatedgenesthatencode
secreted signaling proteins. These proteins are involved in regulating cell fate and
paneming during embryogenesis (51). Seven variants were detected in WNl7A,three
non-coding(two intronic and one 5' UTRvariant),two were coding and two were found
in intragenic ESTsthat were screened. Five of the variants were found in controls and
two (one EST variant and the 5' UTR variant) were only found in one atfected individual
TPRXL(tetrapeptiderepeathomeobox-likeprotein)
TPRXL is a homeobox gene since it has a conserved DNA sequence called the homeobox
that encodes a DNA-binding domain -the homeodomain. Many homeobox gene
products are thought to be involved in early embryonic development, however the exact
function of TPRXL is unknown (51). Two non-coding intronicvllriants weredetectedin
TPRXL,whichwerefoundincontrolsonthescreeningpanelthusexcluded (Appendix 5)
CHCHD4(coiled-coil-helix-coiled-coil-helixdomaincontainingprotein 4)
CHCHD4 is a component of human mitochondria and belongs to a protein fami Iy that has
6 highly conserved cysteine residues within a particular motif in the Ctenninus(51)
Fournon-coding variants were detected in CHCHD4, including two intronicvariants,one
variants (six intronic and seven within the 3'UTR)andtwocodingvariants. All variants
could be excluded except one, c.1073C>T. which was found exclusively in all affected
XPCencodes a protein that is involved in the nucleOlide excision repairpathway(51)
Twenty four variants were detected inXPC. Sixteen were non-coding (five were within
Twenty·three of these variants were found in controls on the screening panel and were
exciuded,howeveronevariant,c.2823+684G>C,wasfoundexclusivelyinallafTected
LSM3 encodes a Sm-Iike protein, which has sequence homology with the Sm protein
family. LSM3 contains the Sm sequencemotif,likeall Sm-like proteins, and may be
involved in splicing (51). There were no variants detected in LSM3
sodium:neurorransmittersymponerfamily(5I).Therewerethirtytwovariantsfoundin
SLC6A6. all of which were non-coding. Twelve were 5' UTR variants. nine were intronic
and II were 3' UTR variants. Twenty·nine variants were excluded from further analysis,
three of which were found in only one affected individual,and 26 were found inthe
controls on the panel (Appendix 5). There were three SLC6A6variants, c.l·2742OG>A.
GRlP2 plays an important role in neuronal cells by acting as a scafTold for the assembly
of multiprotein signaling complexs and mediating the trafficking of its binding partners
(51). There were fourteen variants detected in GRlP2. Eightwerenon-codingintronic
variants and six were coding variants. All fourteen variants were excluded fromfurther
analysis, six were found in only one affected individual and the remaining eight were
C3orfl9 is a hypothetical protein, also known as LOC51244. Twelve variants were
detectedinC3orjl9,allofwhichwerenon·coding.Elevenwereintronicand one was
C3orf20 is another hypothetical protein in theARVD5 critical region that isalso referred
non-coding (three were within the 5'UTRand five were intronic) and seven were coding
FGD5isaproteinofunknownfunctionbutitmayactivatemembersoftheRas.like
family of Rho-and Rac proteins, andlor play a role in regulating the actincytoskeJeton
and cell shape (51). Ten variants were detected in FGD5,sevenofwhich werenon-
coding intronic variants and three were coding. Six of these variants, c.934G>A,
c.2186+22G>A, c.2187.82G>A,c.2220G>T,c.2613+50c>Tand c.3085·74G>A,were
foundexciusivelyinalltheaffectedindividuals(Appendix5),Onlyfour were excluded,
NR2C2 (nuclear recepfor sub!amily 2, group C, member 2)
NR2C2 is a member of the nuclear hormone receptor family, and acts as a ligand-
activated transcription factor (51). Nine variants were detected inNR2C2. All variants,
butone,c.J685G>A,werenon-coding. Threeofthesevariants,c.855+70G>A.
c.1848+365T>A,andc.1848+2965_1848+2966insGATA,wereofinterest because they
were ex.clusively seen in all affected individuals on thepaneJ (Appendix. 5). The
remaining six variants were ex.cJuded. One was detected in only one afTectedindividual
MRPS25 is a nuclear gene that encodes a mitochondrial ribosomal protein, whichaicisin
protein synthesis within the mitochondrion (51). Six variants were detccted inMRPS25,
all of which were non-coding. One variant was within intron 2 and the remaining five
onlyoneafTccted individual and the other three were seen in conuols on the panel
(Appendix 5). One variant, c.522+l059G>A,wasobserved in all afTccted individuals
ZFYVE20(zinc fiogerFYVEdomain--<:ontainingprotein 20)
ZFYVE20 is a Rab4lRab5 efTectorprotein that acts in earlyendocytic membrane fusion
and membrane trafficking of recycling endosomes (51). Seven variants were detected in
ZFYVE20.0nevariant,c.I734C>G,wascodingandsixvariantswerenon-coding. The
non-coding variants consisted of one intronicvariantand five 3'UTRvariants.All
variants were excluded because they were detected in controls (Appendix 5)
CAPN7isamemberofthecalpainfamilyofproteins,whichareawell-conserved family
of calcium-dependent, cysteine proteases. TheexactfunctionofCAPN7ishowever
unknown (51). SixVariantsweredetectedinCAPN7,allofwhichwerenOn-cod~g~f~;:
variants, c.1289+68C>Tand c.1430-28T>C,were of interest since they were detected
exclusively in all the affected individuals on the screening panel (AppendixS).The
coding variants included three intronic variants, two 3'UTR variants and one 5' UTR
Ofthe240variantsreported,inthe20positionalgenes,atotalof18variants were found
exclusively in clinically affected individuals on the mutation screeningpanel and were
2.3.2 Segregation analysis
six individuals from Family 1139 (Global ID: 708,709,710, 714. 716 and 718) were
genotypedforaIl18varianrsandhaplotypeswerecreated(Table2.4,Figure2.Sand2.8).
Two clinically affected individuals 710 and 709 (mother and daughter) who were
detenninedto have theARVD5 haplotype using microsatellite markers werechosen for
this analysis, along with the 21 year old daughter of 709. 714,whowas also previously
detennined to carry theARVD5 haplotype, however, had a recombination between
D3SJ516 and D3S3608 (Figure 2.8). Individual 714 has yet to show clinical signs,thus,
who also showed no clinical signs, was another recombinant chosen for the segregation
analysis (fable 2.4 and Figure 2.8). During the earlier microsatellite analysis a
region in families 69 and 273. However, clinically affected individualsin families 69 and
273 have the telomeric portion oftheARVD5 haplotype (Figure 2.7A and 2.9),whereas
SegregationanalysisinFamilyl139detenninedthatfiveofthel8variants,XPC
c.2823+684G>C,FGD5c.2186+22G>A,FGD5c.2187-82G>A,FGD5c.2220G>T,and
2.4 and Figure 2.8). Of the remaining 13 variants that segregated on the ARVD5
haplotype,twovariants,HDACllc.369+18_369+19insGandSLC6A6c.I-27420G>A.
were excluded as being the ARVD5 mutation because they were observed on at leastone
otherhaplotypethatsegregatedthroughFamilyI139(fable2.4).lnadditionto the
yeliowARVD5hapiOlype,HDAClJ c.36!»18_36!»19insGalso segregated on the red,
greyandorangehaplotype,andSLC6A6c.l·27420G>A segregated on the blue haplotype
(fable 2.4). ElevenARVD5 variants remained of interest (fable2.4-highlighted grey)
AllelefrequenciesoftheilARVD5variantsweredetennined
considered common with allele frequencies ranging from 9to 55% (fable 2.4). The
remaining five, however, were rare alleles «1% of the alleles screened) with frequencies
between oand 0.600/0 (fable 2.4). The first rare allele to be screened in all clinically
individuals screened positive for this variant. The affected membersoffamilies69 and
273 were wild-type for that allele (Figure 2.9). Family 69 had three individuals(two
female,onemale)withprimaryclinicalafTectionstatusandtwofemaleswithsecondary
af'fection status, all of whom, screened negative for that variation,and Family 273 had
two individuals with primary affection status that screened negative aswell (Figure 2.9)
Those two families previously defined the new centromeric boundary by identifyinga
crossover point is unknown, however, FDG5lies within those two markers (Figure2.7B)
thus suggesting that the recombination occurred more telomeric than FGD5(c1oserto
D3S3595). Threeothe,mrevariants,MRPSZ5c.522+I059G>A,CAPN7c.128!»68c>T,
andCAPN7c.1430·28T>C (Table2.4),were located between these markers as well, and
weremorecentromericthanFGD5(Figure2.7B).Theaffectedfamilymembersof
families 69 and 273 screened wild-type for those alleles as well (Figure 2.9)
The only rare variant that was shared by all clinically affected subjects across all I5
families was TMEM43 c.I073C>T (p.S358L) (Figure 2.iO). In fact, TMEM43
c.I073c>TwastheonlyrarevanantretainedonkeyrecombinantARVD5haplotypes
identified in clinically affected individuals from families 69 and 273 (Figure 2.9). This
2.3.4 TMEM43 mutation screening in ARJlD5linked families
All available subjects bom at a priori 50010 risk (n=295) across the 15ARVCfamilies
were sequenced for the presence of the c.I073C>T TMEM43 variant (Figure 2.6). All
clinicallyafTected individuals with primary affection status (n::::83/83.40 males, 43
fema]es) were mutation carriers. All individuals with secondary affection status
(n::::23t23.8males, 15 females) werea]so mutation carriers. Twentypercentofclinically
unaffectedindividuals(n=38/189,IOmales,28females)weremutationcarriers(Figure
2.6). The clinically unaffected mutation carriers were at a median age of22 and 33 years
for males and females, respectively. The 151 subjects with no clinical signs who did not
2.3.5 Additional evidence supporting TMEM43 as the cause of ARVDS
After screening all available spouses (n=47) and population controls (n=161 ) for the
TMEM43 variant, no mutation carriers were detected (416 mutation negative
chromosomes}(Table2.4).Also,c1inicallyunaffectedadults(fromARVD5famities)
who shared distal sectionsoftheARVD5 haplotype that lacked the TMEM43 mutation
were identified (Figure 2.11). There were several cases where individuals, with no
clinicalsignsofARVC,hadthecentromericportionofthediseasehaplotype,including
c.J289+68C>T,andCAPN7c.1430·28T>C. These individuals included individual 708
(also known as 1139.016),a female from Family 1139 who is in her late 40s with n0
clinical symptoms to date (Table 2.4 and Figure 2.5 and 2.8),and three other individuals
from Family 64 with no clinical signs, individual 0064.1011 (a female in her late 60s)
(Figure2.2),andindividuals0064.0029andOO64.0030(femalesintheir late 40s who are
not in the reduced pedigree in Figure 2.2). There was also one case where an individual
from Family 964 (0964.0004-a male in his late 60s with no clinical signs) was
determined. through fine-mapping. to have the telomeric portion ofthe disease haplotype.
2.3.6 ARVC linked to the ARVD5 locus is caused hy a missense
mutationinTMEM43
TMEM43 (Genbank: Accession number NM_024334) has 12 exons, and encodes a 400
amino protein known as transmembrane protein 43 and/or LUMA (185,187). The
protcin is 98% similar to the mouse protein and is well conserved across aJl eukaryotic
and prokaryotic species (Figure 2.12). In 200I,TMEM43 was first recognized as an
inner nuclear membrane protem (I85),a result that was later confirmed in another
independent proteomics study (188). Interestingly, the first characterization of the
TMEM43 proteinwasrecentlypublished,linking it to proteins known to causecardiae
disease (187). Bioinfonnatic analysis ofTMEM43 predicts ittobea membrane protein
with several potential post-translation modification sites {Figure 2.13). However,unlike
the transmembrane proteins of the desmosome (desmocollin anddesmoglein),TMEM43
desmocollin and desmoglein show less than 10% identity and less than 12% similarity.
Themutation,p.s358L,occurswithinthethirdpredictedtransmembranedomain and is
highlyconservedinmammalian,avian,amphibian,andinsectortho!ogs (Figure 2.12 and
2.13). Interestingly, a leucine residue at this position is found in the bacterium Rhizobium
/otibut it is not found in any multicellular organisms (Figure 2.12). Thep.S358L
mutation is also predicted through bioinformatic analysis to have adeleteriouseffecton
discovery. By studying 15 ARVCNewfoundland families and using a positional
mappingapproach,TMEM43wasidentifiedasthecausai gene forARVD5. TheARVD5
extended seven generations and contained 200 individuals (146). Tenlivingaffected
pedigree. Afterarwo-point linkage analysis, marker D3S36J3 on 3p25 (LOD score 6.91
(9=0» was detennined to be the only marker with a LOD score above 1.5. and fine
mapping identified a 9.3 cM disease haplotype between markers D3S3610and D3S3659.
Despite that the pedigree of Family 64 has currently been extended from 200 to 1200
individuals, the disease region would not have been reduced to 2.36 Mb if the additional
ARVC families, especially families 69 and 273. were not available for study.Affected
detected in the original mapping paper was confinned in families 76 and 453. where all
mutation screening panel were very important for efficiency and reliability. With357
amplicons required to amplify the 275 exons of the 20 positional candidalegenes,Sanger
sequencing was used to identify all point mutations and small insertions/deletionswith
certainty. The screening began by selecting the best candidates based on expression,
function and prior screening knowledge. However, in the end all posill0nal candidates
were screened. Many clinically affected individuals with theARVD5 ancestral haplotype
were identified during the reconstruction of the haplotype (175),however,only a select
controlstobepiacedonthemutationscreeningpanelwascriticalaswe1l.SinceARVC
is difficult to diagnose, controls were chosen if they were not blood reiated to the 15
families, did nOlhaveclinical signsofARYC, and werepreviouslydetenninednotto
havetheARVD5haplotype. Screening four clinically afTected and three unafTected
controls,alongwithaH20control,enabledl2ampliconspersequencingplate,making
After mutation screening, a critical process of elimination was carried out to identify the
disease variant. Therewereinitially240variantsdetected,howeveronly18variants
were found exclusively in clinically afTected individuals on the mutation screening panel
andwerefunherinvestigated.Segregationanalysisdeterminedthatllofthosevariants
segregated on theARVD5 haplo()'pe, but after calculating the Newfoundland population
aJlele frequencies only five rare variants remained of interest. Four of those variants
happened to be located between markers D3S3595 and D3S3613. where the critical
these two key recombinant families. identifying the TMEM43 variant, c.1073C>T.as the
onlyrareARVD5variantthatwassharedbyallaffectedindividuaiswithintheiSARVC
protein is evolutionarily conserved and the presumed amino acid substitution(p.S3S8L)is
predicted to be deleterious. This mutation was not detected in spouses or population
controls. Bengtsson and Otto specifically determined that TMEM43 interacts with
emerin and participates in controlling its distribution along the nuclearmembrane(187)
Emerin [MlM#300384] is a lamina-associated LEM-domain protein that causes an x-
linked fonn of Emery~Dreifussmuscular dystrophy (EDMD) [MIM #310300] (189)
EDMDisalaminopathy.whichareagroupofraregeneticdisorderscausedbymutations
in genes encoding proteins of the nuclear lamina and are generally due tomutationsinA-
()'pelamins(I90). Bengtsson and Otto also determined thatTMEM43 binds both A-and
B-t'ype lamins and depends on A-()'pe lamins for its localization. Thus, they suggested
thatTMEM43 is an integral nuclear membrane protein that stnlcturallyand functionally
organizes inner nuclear membrane protein complexes and has the potential to cause
pathological changes to the nuclear envelope (187)
Re<:ently, signaling pathways have been implicated in ARVC pathogenesis as well (171,
191). For example, plakoglobin,when freed from desmosomal complexes,translocatesto
the nucleus where it competes and opposes the action ofj:kalenin and down regulatesthe
canonicaIWNTIj}-cateninsignalingpathway(171).SuppressionofthecanonicaIWNTIf}-
C81eninsignalingup-regulatestwoadipogenictranscriptionfactors,CIEBP-a.[MIM
#116897] and PPAR'Y [MIM #601487] (171). A genome wide scan for peroxisome
proliferalorresponseelements(pPREs)identifiedI085potenlialtargetgenesofPPAR'Y,
including TMEM43 (192). IfTMEM43 is a part ofanadipogenic pathway regulated by
PPAR'Y,thenperhaps, dysregulation of this pathway may explain the fibrofany
replacemenl of the myocardium in ARVCpalients.
After the third desmosomal gene,PKP-2,was identified as a causalive ARVC gene in
2004,itwassuggestedthatARVCmaybeadiseaseofthedesmosomes(156). This
initiatedARVCgenediscoveryeffortsusingacandidalegeneapproach. Several groups
screened DSG2and DSC2, rwo genes that encode desmosomal cadherin proteins,in
ARVCprobandsandidentifiedtheARVDJOandARVDlJloci,respectively(161-165).
Another group screened plakoglobin (JUP),the recessively mU1ated Naxos disease gene,
ina Gennan family with aUIOsomal dominantARVC and identified the first autosomal

assays with ARVC-mutantconstJucts showed twofold increaseofTGFp-3 expression
compared 10 wild-type constructs (142), which may explain the excess fibrosisobserved
in ARVC cases. However,ilisimportanttonotethatnomutationshavebeenreportedin
theotherfamiliespreviouslylinkedtoARVDlrnutations(133,141),whichquestionsthe
Stricdy using the lntemarional Task Force criteria (126) to diagnose ARVC in this study
was difficult because of the large historic nature of the pedigrees (SCD being the primacy
disease feature) and the lack of availability of tertiary testing centers. Therefore,asubset
Mutation status for the defined three groups was as follows: primary affection status
(clinically afTected) (83/83), secondary affection status (23n3) and clinically unaffected
(38/189). All individuals that had either primary afTeclion status or secondary affection
status were mutation carriers. This highlights the variability of the expressedphenotype
Also, 20% of people that had no clinicsl signs were mutstion carriers; theclinically
males and 33 years for females). This can be explained byage-relatedpenetrance.The
results ofa penetrance study performed by Kathy Hodgkinson showed that ARVC was
fully penetrant in males by the age of63 and in females by the ageof76 (174)
In regard to future perspectives, the size of the ARVC cohort in this study provides an
opportunity to compare and define ARVC·specific clinical features inaf'fectedand
unatTectedsubjects. One hundred and foIty-four individuals with the TMEM43 mutation
areavailableforstudy,aswellasl5lunaffectedcontrols.Previousstudiesthatassessed
theARVCphenotypeinpatientswithmutationsinplakophilin-2(194),desmoglein(163)
andplakoglobin (l95) typically evaluated clinical features in onlymutationcarriers,with
the assumption that all cardiac signs present in affected subjects are due to the underlying
genetic defect. However, it may be that some clinical features are due to the genetic
background of either the family or the source population, which would be interesting to
Sludy using this cohoI1. Funhennore, due to the serious repercussions ofARVC. this
gene discovery has enabled a clinical diagnostic test to be designed and offered toat-risk
family members, which will help with early diagnosis and the proper medical precautions
that need to be taken inordertosavelives-implantationofan implantable cardioveI1er-
defibrillator. Finally, recent functional studies suggest that the responsiblemechanism
forthepathogenesisofARYCisthesuppressionofcanonicalWNTsignalingbynuclear
plakoglobin, which enhances expression ofadipogenic factors and 1eadstothe
differentiation ofa subset of cardiac progenitor cells to adipocytes (l 71).ARYCisthe
first disease to be recognized as disrupting the difTerentiation of cardiacprogenitorcells
(196),and it will be interesting in the future to see what therapeuticdevelopmentsunfold
As Bengtsson and Otto suggested (187), TMEM43 has the potential to cause disease
FunctionallystudymgtheeffectsoftheTMEM43mutation(p.S358L)canvalidate its
pathogenic effect and will enable a greater understanding of ARVC pathogenesis.
Detecting additional TMEM43 mutations in ARVC probands from other populations
world-wideimpactonARVC.Interestingly,afteranalyzingthepersonalgenomeofa
patient with a familyhistoryofv8SCulardiseaseandsuddendeath,and queryingdisease-
specific mutation databases, Ashelyetal. reported rare variants in three genes associated
with SCD, including TMEM43 (197). Also, most recently, two TMEM43 sequence
variants,includingc.I073c>T,wereidentifiedinaDanishARVCcohort.Segregation
analysis indicated that the Danish TMEM43 c.I073C>Tvariant segregated with ARVC in
theafTectedfamily(l98).ltwouldbeinterestingtodeterminethroughhaplotypeanalysis
same report, evaluation of the expression of the desmasomal protein plakoglobin in
suggests that theARVD5 mutated protein TMEM43 may share a final commonpathwaY
how these gene products link to a common disease mechanism
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Figure 2.6: Affectionstatusaod mutation screening of all individuals born at a-
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Chapter 3: Non-syndromicsensorineuralhearinglossina
large extended Newfoundland family maps to Xp21
3.1.1 Sound and measurement of bearing
Sound is perceived through the detection of sound waves, which are pressure waves that
propagate through the air. All sound waves have particular frequencies; frequencyis
time. The unit of frequency measurement is the hertz(Hz),whichdetectsthe number 0 f
cycles per second. Hearing is measured in decibels (dB) across all frequencies. The
burst 50010 of the time at a certain frequency. Hearing is considered nonnal if an
that depicis the ability to hear sounds at different frequencies (Figure 3.I),anditis
Deafness afTects 6·S%ofthe population in developed nations and is the most prevalent
Approximately,linlOOOnewbomsisprofoundlydeaf,anotherlin300has a congenital
hearing losstoa lesser degree, and an additional 1 in 1000 become profoundlyhearing
3.1.3 Classification of hearing loss
There are several ways to classify hearing loss. Firstly, upon analysis of an audiogram,
the severity (and the corresponding frequency) of the hearing loss can bedetennined
The World Health Organization (WHO) divides the severiryofhearing impainnent into
several grades: mild orslight(26-40dB),moderate(41-60 dB),severe (61-80 dB) and
profound (81 dB or gresler); and the frequency of hearing loss is designated as 10w«500
Hz), middle (501·2000 Hz) and high (>2000 Hz) (199). Se<:ondly, one can classify
hearing Joss based on age of onset. lfhearing Joss develops before the abiJitylO speak it
is known as pre-lingual,which mayor may not be congenital. Ifit occurs after language
development it is known as post-lingual. A third way to classify hearing loss is based on
its stability over time. If the hearing loss worsens over time it is known as progressive
Hearinglosscanalsobeclassifiedbasedonetiology.ltcanbeduetoenvironmental
factors, genetic defects, or a combination of the two (mixed). It is estimated that at least
50% of pre-lingual hearing loss is genetic, 25% is environmental (infections, trauma, etc.)
focusing on the physiological malformation, hearing loss can be definedasconductive
(due to external ear anomalies or abnormalities of the ossicles in the middle ear),
central (due to defects in the Vlllth nerve, brain stem or cerebral cortex},and mixed (a
3.1.4 Inherited hearing loss
Inheritedhearingloss,inmostcasesdescribed,ismonogenic(200}.hcanbeinherited
inheritedasa syndrome with additional manifestations. The inheritance pattem can be
2009 reviewbyHilgertetal.,itwasestimatedthat 70010 of inherited deafness isnon-
syndromic,with800lobeingrecessive(DFNB},IS-20%beingdominant(DFNA},-I%
being X-linked (DFNX) and at least 1% being V-linked or mitochondrial. Non-
syndromichearing loss is generally sensorineural. Autosomal dominant deafness is
generally post-lingual and progressive, and recessive deafness is generaIlypre-lingual
3.1.5 Heterogeneity of deafness
Deafnessisverygeneticallyheterogeneouswithapproximatelyl%ofall human genes
involved in the hearing process; proteins comprising ion channels, the extracellular
matrix, the cytoskeleton, and transcription factors all interact for proper auditoryfunction
(htlp"lIwybhOl.ua.8'i,belhhhO,therehavebeenoverI20non-syndromicdeafnessloci
identified for autosomal dominant (DFNA) and autosomal recessive (DFNB) deafness
combined (38). The number identifying the locus, for example DFNA/, represents the
chronological order in which the loci were discovered (38). Of the identified loci, over
45 causative genes have been identified (200). Thegapjunclionprolein bela 2 gene
(GJB2)(MIM #121011], which encodes the protein connexin26, is the moSl common
cause of recessive deafness inmost populations and in some populations is the causeof
50% of deafness cases (204). There are over 220 GJB2 mutations that have been reported
(TheConnexin-DeafnessHomepage:http://davinci,crg.esldeafnesVindex.php)(200),and
the moSl commonly reported mutation in Caucasians with European ancesuy is c.35delG,
Clinical heterogeneity is defined as the development ofdifferent c1inical phenotypes from
different mutations within the same gene. DifTerent mutations in many non-syndromic
deafness genes cause syndromic fonns of deafness as well,and a good exampleofthisis
Usher syndrome [MIM #276900], which is associated with deafness and bIindness. This
syndrome nonnallypresents with pre-lingual sensorineural hearing 10ss,withorwithout
difTerent Usher syndrome phenotypes that difTer based on vestibularfunction and retinitis
pigmentosaageofonset(207,208). Many non-syndromic deafness loci and Usher loci
have the same causative gene (209), for example, DFNB/2 [MlM #601386] andUsh/D
[MIM#601067] are caused by cadherin23 (CDH23) [MIM #605516] rnutations (210,
3.1.6 Hereditary deafness gene discovery
(i) Mapping bearing loss loci
Due to the generic heterogeneity of deafness, gene discovery efforts have been most
5llcccssfulinisoJatedpopulationsbystudyinglargeconsanguineousfamilies.
Approximately 80% ofnon-syndromic deafness cases are recessive, and because of the
typical small pedigree sizes that are ascertained in most first-world urban areas, linkage
has been more difficult in those diverse populations (201). Also, since there are overlOO
known loci for non-syndromic deafness the likeliness that two random, hereditary
Therefore grouping multiple deafness families for linkage analysis, whichisatraditional
method for gene identification and was used for the identification 0 fBRCAI,isgenerally
nOlveryuseful(201,212).Consideringthatdeafnessisacommondisorder and very
genetically heterogeneous well as easily influenced by environmental factors,
phenocopies can be present even within one hereditary deafness family. This can also
hinder gene discovery efforts, therefore it is best if the clinical characteristics are well
In populations such as Tunisia and Pakislan.consanguinity is common and preferred
(213,214). Religious and culrural beliefs, as well as social and economic considerations
all influence attitudes toward consanguinity. For example, in certain populations
consanguineous marriages are believed to strengthen family ties and reduce financial
problems (215). This belief system results in married couples who share many of the
prevalence. Autozygositymapping, which is the mapping ofreccssive allelcs identicatby
decent in consanguineous familics, has been perfonned in these populations to fmd
deafnessJoci. ForexampJe,DFNB8[MIM #601072) andDFNBIO [MlM #605316] were
independently identified through linkage analysis in two large consanguineous Pakistan
causative gene, transmembrane protease serine 3 (TMPRSSJ) [MlM #60551 I] (218).
(ii) Identifying causal geneswitbin bearing loss loci
Once deafness loci have been mapped,thereare several ways to prioritize the selectionof
positionalcandidategenesforscreening.Onemethodofselectionisbased on gene
expression. Immense effort has been made to identify genes selectively expressed inthe
cochlea and to detenninewhetherthese genes map to known deafness Ioci(2l9).A
mousecochleacDNA library was established and it has aided inthegenediscoveryof
several deafness genes. This approach was used to identify the gene otofer/in(OTOF)
The use of animal models, pacticularly the mouse model,has also been asuccessfu1way
to identify deafness genes. When an unidentified deafness gene has beenmappedtoa
previously identified, that gene would be a key candidate for screening. Thisapproach
224). In addilion to aiding in gene discovery, animal models for hereditary deafness also
enable the determinalion of the phenotype's anatomical, biochemical, andcellular
used for morphology studies ofmutant-MYOl5A deafness, which showed abnonnally
3.1.7 Hearing loss in the population of Newfoundland
Hearingimpainnent appears to be prevalent in the Newfoundland population. panicularly
on the south coast of the province, and three large south coast families have previousIy
been studied to identify causal deafness genes. Positional cloning inaNewfoundland
(south coast) family with autosomal dominant low frequency hearing 10ssidentified
wolframin (WFSf) fMlM #606201], the gene previously known to cause Wolfram
syndrome [MIM #222300], as the causative DFNA38 [MLM #600965] deafness gene
(98). WFSlisthecausativegeneforlow-frequencyhearinglossatDFNA6I14/38, which
were separately identified loci that were first thought to be non-overlapping loci at4p16.3
(98,226-228). There are now at least 12 additional families with aulosomaldominant
low frequency hearing loss that have WFSI causal variants, all of which are missense
individuals presented with an autosomal recessive, congenital,non·syndromichearing
another' in exon 8, c."82+3d,:IGAG. Affected family members were either homozygous
previOl"ly ma,pped lWNB2;f locus. In 2003, Ahmed et al. took a candidate gene
the 47 probands participating in the study were solved. All six probands were determined
are considered to have a potential for gene discovery. One extended family was the only
family to have an apparent X-linked mode of inheritance (no male-to-maletransmission
and variable expression in females). This family has major potential for gene discovery
3.1.8 X-linkednon-syndromicdeafness
X-linked non-syndromicdeafuess is relatively rare, estimated to contribute to
approximately I%ofall non-syndromicdeafuess cases (66). There is however an excess
of of males among the deaf (237) and X-linked deafuess can explain this excess; ilis
eSlimated that approximately 5% of pre-lingual male deafness is X-I inked (237-239). X-
linked disorders are caused by mutations in genes on the X chromosome, one of the two
A falherwith X-linked hereditary hearing loss will not pass the mutation to hisson(s)bul
will pass il to all of his daughters. A female who is a carrier has a 50% chance of
transmitting the deafness-causing mutation with each pregnancy. Sons who inherit the
hearing loss are considered obligate heterozygotes (unJess one can prove that the mutation
is de novo) (240). Daughters who inherit the mutation either from their motherorfather
3.].9 Variable expression in X-linked diseases
Variable expression of X-linked traits in heterozygous females is common and rnaybe
due to the specific mutation itselfor the mechanism of X chromosome inactivation,which
operatesinfemalestobalancegenedosageinmalesandfemales(24I).Xinactivationis
the phenomenon in female mammals by which one X chromosome, either the matemally
orpaternallyderivedX,israndomlyinactivatedinembryoniccel!s.Onceafemale
diploid cell has an X chromosome inactivated. the same X is inactivated in all descendent
cells (240). Dobyns et aI., 2006,recently suggested to refer to X-linked traits as solely
frequent occurrence of variable expression across many phenotypes in female carriers
An X-linked trait was once considered dominantly inherited when thedaughterofan
passed to an affected son from an unaffected mother (in this case the mother was
3.1.10 X-linked non-syndromicdeafness loci
To date, eight non-syndromic deafness loci have been designated as X-linked(DFNJ-8)
(Table 3.1) (38). However.DFNJisnolongerconsideredanon-syndromic X-linked
deafness locus. The large Norwegian family originally linked toDFNJ (242) has since
addition to hearing loss (243). DFN5and DFN7havebeen withdrawn from the list and
theDFN8 locus has been reserved but the map Jocation not released. Therefore, only four
mappedDFNlociexiSl,DFN2,DFN3,DFN4andDFN6. ThecausativegenesforDFN2
non-syndromicX-linked loci as DFNX (66),therefore the current designation in OMIM
X-linked deafness was first reported in the 20lh century with at least seven different
linkagestudieswasperfonnedonX-Jinked,non-syndromic,deafnessfamilie5 from which
one large locus on Xq13-q21 was identified (246-248). Cytogenetically detectable
were clear audiological differences between the patients with deletionsandthepatients
chromosomal region, hence they were given distinct designations ofDFNXJ(DFN2)and
(i) DFNXl[MIM#304500]
DFNXI was officially mapped in 1996 using a British·American family with a
congenilal. profound,sensorineuraJ, X-linked hearing loss, originally describedby
female carriers. Eight of those females had mild-moderate hearing loss uponaudiological
testing, the remainder either had anonnal audiogram or their hearing status was
of2.9J«()==6)atdinucJeotiderepeatsatCOUA5andDXSII06.Twoadditionalfamilies
American family with a profound,sensorineural, X·linked hearing loss, however the
deafness was post-lingual (252). Cui et al. described a Chinese family with congenital,
profound sensorineural hearing loss (253). The female carriers in these additional
symmetrical hearing loss around lOOdB and females who have a hearingdefcct detected
gene[MIM#311850],whichencodesphosphoribosylpyrophosphate(pRPP)synthetase
1. Screening the three previously identified DFNXI-linked familiesrevealedmissense
(ii) DFNX2[MIM#304400]
Linkage analysis for the DFNXl locus was first perfonned ina large Dutch kindred with
X-Iinked,progressive, mixed deafuess with perilymphatic gusher during stapes surgery
(246). ThegeneforDFNXlwaslocalizedtoa500kbregiononXq2landwasidentified
as POU3F4 [MIM #300039], using five unrelated families that mapped to DFNX2(245).
phenotype is described as a profound,sensorineural deafness with or without a
conductive component associated with 8 unique developmental abnormality of the ear
(example: perilymphatic gusher after stapedectomy, and a dilated internal auditory
meatus). It is also known as deafness with stapes flX8tionsyndrome, perilymphatic
gusher-deafnesssyndromeorNancedeafness(160,25S).lnaffectedmalesthehearing
loss is congenital and rapidly progresses to severe hearing loss of all tones inthefirst
decade. Female carriers may show a slight hearing loss with or without the perilymphatic
POU3F4(also referred to as BRAIN4) encodes a POU-domain transcription factor andis
part of atranscription factor family with a homologous DNA-binding (pOU)domain.ln
[MIM #602460], also cause a deafness phenotype (DFNAJ5 [MrM #602459]). Mutations
in POU3F4that have been implicated in hearing ioss includepointmutations and small
deletions, panial or compiete deletions of the POU3F4 gene, and deietionsand
dupiicationsofDNA proximal to but not includingPOU3F4,suggestingthe presence of
an important regulatory element that aff'ects POU3F4 function (249,254,256-260)

variable expression in affected female phenotypes (262). It is possible that DMD is the
causative gene, and there is a mouse model. mdx, with a stop codon indmdreportedto
have auditory problems (263) bUI that dala could not be validated (264).
(iv) DFNX4[MIM#300066)
Del Castillo et al. linked hearing loss in a single Spanish family, wilh bilateral,
sensorineural and progressive hearing loss to 12 Mbregion on Xp22 (265). The age of
onset in males was approximately five years, and the hearing loss initiallyaffected only
the high frequencies. Thehearinglosslaterprogressedtoaffectallfrequenciesand
becamesevere·profound.Carrierfemaleshaveamoderatehearinglossinthehigh
frequency and the onset is generally in the fourth decade. No other DFNX4 families have
been reported,but expansion of the Spanish family later refined the disease linked region
This chaplerconcentrated on the disease gene identificalion oflheonlyidentifiedhearing
loss family with an apparent X-linked modeofinherilance in the Young Iaboratory.
Haplotype analysis of the X chromosome was first carried out to identify chromosomal
regions that were exclusively shared by affected individuals, followed bythescreeningof
Family 2024 (Figure 3.2) was recruited through the Provincial Medical Genetics Program
ofEastem Health, as part ofa Newfoundland population-based, hereditary deafness
study. This project was approved by the Human InvestigationCommineeofMemorial
University (#OJ.l86) and the Research Proposal Approval Committee (RPAC)ofEastem
Health,St. John's, NL, Canada. All recruited individuals that consented to the studyhad
a blood sample taken forD A isolation and cell-line establishment. Family2024isan
extended 6 generation family (Figure 3.2) that was first recognized by Dr. ClaireNeville
Smith in the early 1970s as two separate families (families 24 and 25). Theprobandsfor
family 24 and 25 were 2024.3019 and 2024.3000, respectively (Figure 3.2)
the historic nature of this pedigree most individuals weredesignated as having hearing
lossbyeitherDr.Smithherself,orfromafamilyhistorytakenbyDr. Smith in the early
1970s;however, limited medical records were included in the archived family files.
Deafness was only confirmed through medical records (audiology report or doctor's
report) in IS individuals. TherewereatotalofSOapparentlyafTectedindividualsinthe
family and DNA was collected for seven of them (all of whom had the proper medical
records available). An individual with known audiology had pure-tone audiometric
evaluationstodetenninethehearinglossseverityacrossallfrequencies.CT(computed
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tomography) scans were performed on two affected individuals, one male and one female,
age of onset. Threegroupswereestablished;(l)ageofonsetunderlOyearsofage.(2)
age of onset over the age oflO, and (3) age of onset unknown (Figure 3.2).
A genotype scan of the X chromosome was perfonned on five individuals, four affected
(2024.0000),andhislWograndchildren(2024.AOOland2024.AOO2).Theunafl"ected
family (spouse 2024.0000) (Figure 3.2). Microsatellile markers from Panel 28 of the ABI
PRJSMLinkageMappingSelv2.5-MDIOkitwereusedforthescan. Panel 28 consisted
of 18 microsatellite markers spaced approximately 10 cM across the X chromosome
(Appendix 6). Markers were labeled with one of the four fluorescent dyes; 6-FAM
(blue),VIC(green),NED{yellow)orPET(Red).AIXPCRmixhadafinalvolumeof
7.5 ~I, consisting of 0.75 ~I of lOX PCR Buffer, 0.75 ~I ofdNTPs (250 mM), 0.75 ~I of
MgCI, (25 mM), 3.49 ~I of H,O, 0.06 ~I of Taq DNA polymerase (5 Unitsl~I), 0.5 ~I of
primer mix, and 1.2 ~I of25 nglul genomic DNA. Amplificalion was carried out by an
a 15 second 55°Cannealingperiod,anda30second72°Cextension period,followed by
20cyclesofaI5second8~Cdenaturingperiod,aI5second55OCannealingperiod. and
a30second72OCextensionperiod,whichwasultimatelyfollowedbyatOminute72°C
Afteramplification,PCR prodUClS were pooled forgenotyping. PCRsampies from one
individualwerepooledtogetheriftheampliconsfromeachprimersetwerelabeled with a
different dye or if the amplicons were different sizes (non..overlapping) but labeled with
the same dye set. A total of2-4 amplicons were pooled together using I ~I of each PCR
sample,O.4~lofGeneScanTM 1200LlZ@sizestandard,and9jJ.lofDMF(ABIPRlSM
Linkage Mapping Set Version 2.5 User Guide and Panel Guide). Samples were
electrophoresed on the ABI 3tOO or the 3130,and the data was analyzed using
3.2.4 Building X cbrnmnsome baplotypes
Haplotypes (combinations of alleles that are transmitted together) of the entireX
chromosomewerebuiltmanuallyusingalltypedmarkers,inordertodeterminewhich
regions were shared amongst the affected individuals. When building haplotypes, phase,
defined as knowing from which parent a child inherited the alleles, and recombinants
(defined in Chapter I) need to be detennined; studying families with threeormore
generationsmakesthistaskeasier.lnregardtotheindividualsgenotyped in Family
2024,phase was simply detennined for the females (2024.0000 and 2024.A0002) because
thepatemal X chromosome does not recombine (there is only one copy) and their father's
3.2.SFineMapping
Genome Browser homepage (hnp:/Igenome.ucsc.edulindex.htm!?oTeHuman).Atotalof
Thelnvitrogen™TaqDNAPolymerasekit(Cat.#:I0342020)wasusedtoamplifyaII
c:lc:ctrophoresis was no longerperfonned once conditions wc:re optimized. Sampleswc:re
run on the ABI 31000rthe 3130 and analyzed using GeneMapper vc:rsion 4
recruited (lotal=3),thc:ywere typed forthc: markers in the shared region(s) to detennineif
theyhadthesame'affected'haplotype.Recombinantsofthesenewindividualswere
3.2.6 Identifying and screening genes witbin tbecandidate region
hnn:lIgenome.ucsc.edulindex.html?org=Human),andtheMarch2006assembly(NCBI
build 36.1) were used to identify the genomic contigofthecandidate regionand
posilional candidate genes. All genes in Refseq were noted (Table 3.2 and3.3)
Positional candidate genes were prioritized for screening based on expression, function,
previously associations with hearing loss, and overlap with known DFNXloci. The
Morton cochlearcDNA library was used to detennine which genes in the candidate
http:// brighamandwomens.org!bwhhearinglhuman-cQChleaH;sts,8.Spx) (219).
Onlythegenesthatwerelistedinthatlibrarywerescreenedinthisstudy.Forail
expressed genes, primer sets for all codingexons and intron-exon boundaries were
designed using Primer 3 (176). The same trial methodo)ogyused inChapter2,section
2.2.3(i),was applied to determine the optimal amplificationconditions for each primer
set. See Appendix 8 for the primer sequences and amplification conditions.
3.2.7 Creation ora mutation screening panel
A mutation screening panel was established that comprised seven genomic DNA samples
from fouraf'fected subjects and three unaf'fected controls, and one H20 blank. The
and two females (2024.0000 and2024.AOO8). The logic behind using seven DNA
samples and one H20 control was the same as in Chapter 2 gene screening (section
2.2.3(ii».ThispanelwasscreenedforaJlprimersetsundertheoplimalconditionsthat
were detennined above (Appendix 8). The same sequencing protocol was foJlowed as in
3.2.8 Detection of genomic rearrangements in DMD
Thedysrrophin (DMD) gene was a positional candidate in this study, and was also the
positional candidate that Pfisteretal.in 1998 thought caused deafness at DFNX3 (262)
DMD is known to have many exonic duplications and deletions, which can be detected by
MLPA(58,266)byusingMLPAprobemixesP034andP035. MLPA was used in this
study to screen for such mutations. Mixes P034 and P035 contain probes for each of the
79 exons in the longest DMD isofonn (accession numberXl4298). Inaddition,aprobe
is present for the altemativeexonI ofisofonnDp427c.

temperature was reduced to 54°C. While at 54°C, 32 ~I of Ligase-65 mix was added to
each sample and mixed well. That mixture was incubated for 15 minutes at 54°C then
ote: The Ligase-65 mix was made less than I hour before use and was stored on ice. To
make the Ligase-65 mi~3 ~lofLigase-65 buffer A (transparent cap), 3 ~lofLigase-65
buffer B (white cap), and 25 ~I of H20 were initially mixed together. Then I ~I of
Ligase-65(browncap)wasaddedandthecompletemixturewasmixedonefinaltime
In a new PCR plate, 4 ~I of SALSA PCR buffer (red cap), 26 ~I of H20 and 10 ~I of
MLPA ligation reaction were mixed together. This was placed in the thennocycler at
60°C and 10 ~I of Polymerase mix was added, which immediately followed the start of
Note: The Polymerase mix was made less than I hour before use and was stored 0 nice.
To make the Polymerase mix 2 ~I of SALSA PCR·primers (purple cap), 2 ~l of SALSA
Enzyme Dilution buffer (blue cap) and 5.5 ~I of H20 were mixed together. Then 0.5 ~l
of SALSA Polymerase (orange cap) was added and the whole mixwrewas mixed again
The PCRhad 35 cycles, each witha30second95°Cdenaturingperiod,a30second60°C
annealingperiod.anda60second 72°C extension period. After the 35 cycles. the
Separatioo ofamplificatioo products by electrophore5ts
Following the amplification, 1-3 ~I of the PCR reaction, 0.3 ~I of the internal size
standard and 9 ~I DMF were mixed together in an individual well of an ABI96well
plate. The mixrure was incubated for 2 minutes at 940C then held at 4°C for 5 minutes.
The sample was then placed on the ABI-Prism 3100 Genetic Analyzer. For specific
settings see 'Settings electrophoresis instruments' of the MLPA webpage (58)
3.3.1 Tbe bearing losspbeootype in Family 2024 is variable
females)thatwerereportedtohaveheannglossundertheageoflO,andl6individuals
(I male, 15 females) that were flfStrecognized as having hearing lossoverthe age oflO
(Figure 3.2). Of the II total men with a known age of onset, 10 had their hearing Ioss
first reported under the age of 10. Theone male that was reported over the age of 10
(2024.1046)wasacwallyllyearsoldwhenhewasfirstrecognizedtohaveahearing
problem. Of the 17 women with a known age of onset, 15 (88%) had their hearing loss
first reported over the age oflO. Of the female cases where a specific age of onset was
reported,the age ranged from as early as three years to 74 years of age, with the majority
The universal newborn hearing screening, implemented in the early 2000s, was only
perfonnedon one affected male (2024.AOOI) who passed the screening but was
subsequently diagnosed at the ageoflWo. It is nowquestionedwhetherthe result of his
newborn screening was a false negative, as the first audiology report for 2024.AOOlhada
"cookie bite" appearance (Figure 3.3). Followupreportson2024.AOOlalsoshowed
hearing loss progression over time at the higher frequencies
3.3.2 Investigation of the mode of inheritance for this extended pedigree
Historically this family was considered to have a sex-linked mode of inheritance.The
male-female ratio for individuals reported to have hearing loss is,however, 50/50
Despite the fact that the number of affected males is not larger than femalesthereisa
significantdifTerenceinthemaleandfemalephenotypeinregardtoageofonset and

children with hearing loss (Figure 3.2). This is more evidence that arecessivemodeof
3.3.3 X cbromosome baplotypeanalysis
Haplotypes spanning the whole X chromosome were created using all genotyped markers
(Figure 3.5). The paternally inherited chromosomes of females 2024.0000 and
2024.AOO2 were confumed by haplotyping their fathers, 2024.1000 and 2024.0002.
respectively. Phase was therefore simplydetennined for the females because the parernal
chromosome does not recombine. Since phase was known for 2024.0000. the matemaJ
3.5). Onewasa27.6MbregiononXpwithcrossoversoccurringin2024.AOOlbetween
centromeric end (Figure 3.5). They also shared the genomic region around DXSl1060n
Xq. The crossovers occurred between DXS8089 and DXSlJ06 in2024.A002 and
regions were shared,onebetween DXS805J and DXS8090and the other between

3.3.4 Screening of positional candidate genes
and Table 3.3). All 13 cochlea expressed genes were sequenced. The genes that
overlapped with the two known deafness loci,werepreviouslyassocialed with hearing
loss, and had functions related to the hearing process were priorilized for screening.The
Duchenne muscular dystrophy (DMD) gene was the first gene to be screened. This gene
wastheonlygenewithintheregionofhomolygosityof2024.0000,isexpressedinthe
cochlea, and was the key candidate for the DFNX3 locus. ThelargestisoformofDMD
(X 14298) has 7gexonsandexons4S·79 were within the disease interval (Table 3.3)
Sequencing those exons in additton to otherexons from different isoforms that did not
overlap with the exons ofX14298,forexample,exon I ofDp71(Table3.3) revealed no
sequencing variants. o genomic rearrangements were detected either.
The protein kinase RSK.2,along with SMSand PHEXwerescreened next (Table-3.2).
These three genes overlap with theDFNX4 locus, are all expressed in the cochlea and
havebeenassociatedwithhearinglosseitherinhumanorthemouse.RSK2is the causal
gene for Coffin-Lowry syndrome (CLS) [MIM #303600j, a rare form of X-linked mental
retardation characterized by skeletal malformalions, growth retardation,paroxysmal
movementdisorders,cognitiveimpainnentandahearingdeficitinaffectedmalesand
somecarrierfemales(267,268). BothSMSand PHEXhavepartialdeletions in the Gyro
mouse, which is the mouse model for X-linked hypophosphatemia fMIM#307800j,a
disease characlerized by growth retardation, bone disease, hypophosphatemia, renal
defeets, and also neurologic abnonnalities, including deafness, hyperactivity,circling
behavior,andinnerearabnonnalities(269,270).Onlyonevariantwasdeteeted,SMS
c.l70+30c>T(Table3.4).Thisvariantwasfoundexclusivelyinallaffectedindividuals
on the mutation screening panel but according todbSNP has a frequency of over 40% in
Overall, after all 13 genes were screened, a tota! of II variants were detected (Table 3.4)
one of these couJd be deemed pathogenic as they were either not detected in all affected
The hearing loss that segregates in Family 2024 has a pattern that models X-linked
inheritance. Firstly, there was no evidence of male to male transmission. Six affected
males, all togemer, had 15 children. Five of those 15 children were males, and all five
sonswerenotaffeeted.Secondly,therewasasignificantdifferenceinthemaleand
female phenotype in regard to severity and age of onset. After 40 years of age, all
affected males with known audiology had a severe hearing loss, whereas the hearing loss
hearinglossoffemalesover40yearsofage,whichrangedfrommild-moderalet0
moderate-severe, representing a variable hearing loss. Theageofonsetdifferedbetween
reported to have their hearing loss before the age of 10
It is important to discuss that incomplete medical records are not ideal for gene discovery
efforts. The X-linked pattemofinheritance in Family 2024 was determined using a1150
'affected'individua!s(35individualswithout,andI5withtheproper medical records)
in fact, uncertain-some individuals may truly be unaffected. Also, consideringthatin
recollection of the family history, some unaffected individuals may actualIybetruly
affected as well. Both scenarios could change the visible mode of inheritance of the
pedigree. Furthennore, without the proper medical records, the exact deafness phenotype
Pagel430f298

linking rwo separately recruited families, family 24 and 25. The father (2024.1000) of
only individuals with DNA available were from Family 24 and a 13.3 Mbregion was
showoto segregate with the disease through that part of the pedigree. Haplotyping
segregation of the same ancestral haplotype through this side of the family and clearly
The 13.3 Mb region overlaps with rwo knowo loci for non-syndromic, X-linked deafness
Family 2024. It is also possible that this newly discovered disease intervalrepresentsa
DFNX4wasmappedinl996andaclinicaifollowupofthefamilyiaterrefinedtheregion
to an 8.4 Mbregion (66,265). The region has over fifty positional candidate genes (51,
52) and there is no published data stating whether any of them have been screened. Due
to small family size and limited numher of families, this disease-linked intervaleouldnol

Affected males in Family 2024 experience a non·syndromic, bilateral, progressive,
sloping hearing loss that is very severe. The earliest age ofonsel was repol1ed as 2 years
This phenotype seems most similar to that seen in the DFNX4 family, where the hearing
profound at birth. The exact age of onset may nOI be known for previously described
DFNX4 family members or individuals in Family 2024 but theybolh have a bilaleral,
progressive, sloping hearing losswilh similar severity. The earliest hearingtestofan
affected male in Family 2024 was carried out on a2 year old andlhe audiogram resulted
ina'cookiebitt'configuration. Del Castillo etal. showed the early stage ofDFNX4
hearing loss through an audiogram ofa9yearold male whose hearing loss was sloped
and more severelyatTected the high frequencies (265. 271). This was more similar to lhe
follow up audiogramsofthe boy in Family 2024 who was first ttsted at 2 years of age
Affected females in Family 2024 showed variable expression in regard to both age of
onset and severity. In general,there was a much milder hearing losswithadelayedonset
compared to males. This is typical of X-linked disorders, and all previously reported non·
syndromic X-linked deafness loci have female carriers that are affected in the same
manner(245,251,261,265).ThiscanbeexplainedbyX-inactivation. Even though
female cells have two copies of the X chromosome, for gene dosage purposes,one is
inactivated during fetal development. Each tissue in the female bodyisamosaic,a
compilation of two cell types that differ based on which X chromosome is expressed
The degree of mosaicism differs from tissue to tissue and person to person. The

that not all genes orisofonns are annotated. Perhaps there is an unidentifiedcochlea-
specificisofonnofoneofthepositionalcandidategeneswithanindependentpromoter,
or maybe a novel intragenic gene exists that iscompleteiy independent 0 ftheoverlapping
gene. Finally, the remaining positional candidates that happened not to be in the Morton
human fetal cochlear library could acrually be involved in deafness and just not expressed
Typically, the more refmed a critical region, the easier it is to find a disease gene.The
key to refining a disease region is finding crucial recombinants. That is more likeIyto
happenbysrudyingahighnumberofmeioses,inotherwords,byhavingahigh
participation rate. The recruitment efforts for this srudyweregood but, for numerous
reasons, many individuals in the family did not participate. For example, out-migration is
common for the Newfoundland population and many members of Family 2024 sib-ships
currently live out of the province. Also, telephone recruitment ef'forts may not be the best
approach fora hereditary deafness study. Family 2024 had 50 apparently affected
enrollment might narrow the disease region. However, next generation sequencing
(NGS) has the ability to target-capture and sequence desired regions 0 fthehuman
genome in order to identify causative disease variants using a small sample size (56, 277);
so maybe the recruitment problem can be overcome. One future possibiiity would be to
target-eapturethe Xp region and sequence that genomic region in all (ormost)the
af'fected individuals that participated in the genetic study, and some controls. lftheXp
approach would theoretically detect the variant no maner ifit was coding or non-coding
Another possibility would be to exome sequence the affected individuals (277, 278). One
sequencing kit, but this approach would be a way to studydifTerent possible modes of
analyzed first, particularly the genes in theXp region, but the data would beavailableto
have been a large number of diseases associsted with the X chromosome (because of
male hemizygosity and the phenotypic consequence of carrying a single mutation);just
over 8% of recognized Mendelian diseases (342 of 4140) are X-linked (160). This is
despite the fact that the X chromosome has a small number (n=1098) of annotated genes,
representing 4% of all the human genes (273). Progress in gene identification of many
205 X-linked phenotypes for which the molecular basis is known (160). In fact, the first
gene associated with non-syndromic deafness was the X-linked gene POU3F4,thecausal
gene of the DFNX2 locus(66,245). Identifying the deafness mutation in Family 2024
has the potential to help additional families with X-linked deafnessaround the world
Genediscoverieshelpelucidatethepathogenesisofdeafness,whichinvolves
approximately 1% of all human genes. Proteins that comprise ion channels, the
auditory function. Each new finding helps piece together how the earactuallyworks.
For example, in 2005 digenic inheritance involving PCDHJ5and CDH13 mutationswas
reponed to C8use non·syndromic deafness in mice and humans (279). Through functional
analysis it was then detennined that CDH13 and PCDHJ5 interact to fonn tip·links at the
of these proteins is disrupted by either a homozygous mutation in either geneordigenic
the key to identifying deafness genes, detennining their specific function,and ultimately
linking the functionally diverse group of proteins together. This may even lead to new
therapeutic approaches for the hearing impaired in addition to the use of hearing aids and
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Table3.4:ThellvariantsdetectedaftersequencingtheI3positionalcandidate
genes that are e:lpressed in the cochlea.
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Figure 3.7: The 13.3 Mb region between markers DXS999 and DXS12190nXpthat
is shared by all affected individuals.
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breast cancer"depending orl the SF>ecific,nutatio,n (2ggj Attemptsloidentifyadditional
cancer genes (CHK2,ATM,BRJPJ,NBSl,RAD50and PALB2) (37,290-294). Theb",ast
single mutation in either of these genes is enough to increase breast cancer risk (286); in
Furthermore, genome-wide association studies have identified common low penetrant
occurata high frequency in the general populationand,thus, are frequently found in
controls (284). Theexactcausalvariantsandbiologicalmechanismsunderlying most of
mutations in the genes that encode the tumor protein 53 (P53) and the phosphataseand
4.1.3 Higbpeoetraotgeoes
(i) BreaslcQncersuscepllbJJJtygene J (BRCAJ) [MIM#11370S]
high risk hereditary breast cancer families (308). These famiiies shared characteristic
features commonly associated with familial breast cancer: (i) younger age at diagnosis,
(ii) frequent bilateral disease, (iii) the presence of ovarian cancer and (iv) frequent
occurrence of the disease amongst men. Early-onset families obtained an accumulative
LODscoreof5.98 for linkage of breast cancer susceptibility to markerD/7S74,whereas
negativeLODscoreswereobtainedinfamilieswithlate-onsetdisease(308).BRCA/was
cancerwaspreviouslylinkedtotheBRCA/locus(212).Thefivemutationsconsisted of
(iii) a stop codon, (iv) a missense substitution, and (v) an inferred regulatorymutation
(212).BRCA/islocatedonchromosomeI7q2Iandcodesfora7.SkbmRNAtranscript
TheBRCAlproteinisatumorsuppressorthatpiayscriticalrolesinDNArepair,cell
cyclecheckpointcontroi,andmaintenanceofgenomicstability(310-312). TheC-
tenninusofthe protein has two BRCT (BRCAi C-tenninal) repeats that bind pSPxF
phospho-amino acid motifs, and theN-tenninus has a RING (Really Interesting New
Gene) domain th3t binds to BARD I (breast cancer associated risk domain i)(MIM
#6015931,which fonns an E3ubiqutin iigase(312-315). There are at leastthreedistinct
complexesthatBRCAlfonns:BRCAI-A,BRCAI-B,andBRCAJ-C.Differentadaptor
proteins bind the pSPxF motifs to fonneach unique complex. The adaptor proteins are
Abraxas (Abral) for the BRCAI-A complex, BRIPI (BRCAI-interactingproteinl)for
the BRCAJ-B complex, and CTIP (anotherBRCAI interacting protein) for the BRCAI-C
(ii)Breastcancersusceptibilitygene2(BRCA2)1MIM#6001851
The BRCA2 locus was identified in 1994 through a genome wide scan analysis perfonned
onl5high-riskbreastcancerfamilieswhowerepreviouslyunlinkedtotheBRCAJlocus
(319). Thecriticalregionwasa6cMintervalonchromosomeI3qI2-13(319). Ayear
contigsto identify trappedexons within the region, by focusing on a600-kb interval
centeredaroundDJ3SJ7Iwherethegenewasthoughttobelocated.Sixdifferentgenn-
line mutations in the BRCA2 gene were identified (287). BRCA2 codes fora IO.5kb
transcript. It has 27 exons, and exon 11 represents 50% of the coding sequence (309)
The BRCA2 protein is involved in DNA double-strand break repair in homologous
homologousrecombination,whichmayultimatelymaintaingenomicintegrityand
suppress tumor development in cells (320). In 2004, biallelic mutationsinBRCA2were
reponed to cause Fanconi anemia (FA) [M1M #227650], which is an autosomal recessive
disorder characterized by aplastic anemia, cancer susceptibility and cellularsensitivityto
~,-,,-- .,.,._,_ .._-~~
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type5ofFAthataredividedintocomplementationgroups(FANC-A,B,C.DI,D2,E,F,
4.1.4 BRCAl and BRCAl contribution to familial breast cancer and
penetrance
range maybe explained by mutation-specific penetcance because there is significant
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families. Specific examples of additional organs at risk include the stomach,pancreas,
prostate, and colon, with the stomach and pancreas having the highest increasedrisk.For
any particular cancer the increased risk ranges from about 20 to6()01o. Thenonnal
functioningBRCAlandBRCA2proteinsmustbeinvolvedintheprotectionagainsta
variety of cancers, thus the pathways involved must overlap (331)
4.1.7 BRCAI and BRCA2 disease-predisposing alleles
According to the Breast Cancer lnfonnation Core (BIC) database,sequencing variants
havebeendetectedineveryexonofBRCAJ,andinallbutexon)ofBRCA2.Therehave
It was originally thought that frameshift or nonsense mutations that truncatetheBRCAI
andBRCA2proteinswerethemostcommonbreastcancerpredisposingalleles. When
looking at BIC and noting the number of entries of the top 20 recorded variantsforeach
varianttype(frameshift,nonsenseandmissense),thereareatotalof5805frameshiftand
nonsense mutation entries reported in BRCA2 (332). However, missense variants are the
second most frequently reported variant in the database forBRCAJ (with a total of3559
enmes),andthe most frequently reported in BRCA2 (with 6168 entries). ManyBRCAJ
affect on protein function and disease pathogenesis is unknown;detennining ifthese
waystohelpclassifysuchvariantsincludingfunctionalassays(335),segregation analysis
(il) Genomic rearrangements leading to copy number variants in BRCAJ
It was not until three yeacs after the discovery ofBRCAJ and the identification of
hundreds of point mutations and small insenionsldeletions (336, 337) that the first
BRCAlrearrangementwasreported(338).Thisrearrangementwasdiscoveredinalarge
American family with a multipoint LOD score of 3.62 for two markers that flanked the
BRCAllocus;originally,nomutationsweredetcctedafterscreeningthecodingsequence,
thus further analysis revealed a deletion ofex.on 17(338). This three yeardelaywas
attributed to primarily relying on PCR-basedtechniques formutation detection, which
does not readily detect copy number variations. In fact, rearrangements contributing to
theBRCAlmutationspectrumonlybecameapparentaftersequencingthewhole gene and
detenniningthat a very high densityofAlu sequences, which could possibly act as
hotspots for unequal homologous recombination, were located within the gene region
deletions but also included are duplications, triplications, and a combinationofboth
range in size from 510 nucleotides(deletion of exon 22) to 160,880nucleotides(deletion
(iii) Genomic rearrangements leading to copy number variants in BRCA2
Alusequenceintoexon22wasnoted(342).lnI998,a5kbdeletionofthe3'endofexon
to 13 in a high risk US family (345), and an exon 20 deletion in a Danish family (346)
interestingly no otherBRCA2 mutation has been reported in this population. The
c.999deI5 mutation is approximately 20 times more prevalent in Icelandthan the
estimated allele frequencyofBRCA2 in the general worldwide Caucasian population
(347,348),anditprovedtobethecauseof76%(J6I21)offemalebreastcancerinhigh-
riskbreastcancerfamilies(349).ln632Icelandicbreastcancercasesunselectedfora
family history, the BRCA2 c.999deI5 mutation wasdeteeted in 7.7% of female breast
eancerdiagnosedat any age, and 24% of those diagnosed at age 40 years or younger
Another example is the three founder mutations that have been observed in Ashkenazi
Jewish breast and ovarian eaneerpatients. In the Ashkenazi Jewishpopulation,the
BRCA2 e.6174de1T mutation has a frequency of 0.9-1.5%, the BRCAl c.185delAG
mutation has a frequency of 0.8 to 1.1%, and the BRCAl c.5382insC has a frequeReyof
0.13-0.3%. The population prevalence for these three mutations combined is 2-2.5%,
which is approximately 10-50 times higher than the allele frequency in the general world
population (350-352). For breast cancer cases unselected for family history, these
phenon,enatha' inhibits BJ/CAJI2 gene expression. Another possibility (iv) is the
4.1.10 Rarelowtomoderatepenetrantbreastcancergeoes


(iv) Nijmegen breakagesyndromeJ (NBSJ) [MIM#602667]
age groups (294,362). Gorski et al. studied three groups of patients from Poland:(i) 150
consecutive breast cancer patients who were diagnosed under the age of5o and had
histologicalconfinnedbreastcancer,twoofwhich(I.3%)hadtheNBSlmutation,(ii)80
breast cancer patients with a family history of breast cancer in their first-degreere latives,
the mutation, giving it a 0.6% frequency in the general population (362). Steffenetal.
Sludied562 non-selected breast cancer patients from Central Poland and found II
(1.96%) 657del5 mutation carriers. They estimated the risk ofc.657del5 mutation
More recently, a missense mutation in theNBSl gene,p.117lV, has been associatedwith
carried the mutation p.I171V inexon 5. The rate ofp.1I71V mutation in the group of
(v)RAD50[MIM#604040]
RAD50is8partoftheMreilproteincomplex,whichisimportantforrecombination,
repair, and genomic stability. RAD50wasscreenedformutationsinl51northemFinnish
breast cancer families as partofa process todetennine if any Mrell complex genes

4.1.11 Moderately penetrant genes with foundermulations
4.1.12 RAD51C [MIM #602774J- a third highly penetrant breast cancer
gene
The candidate gene approach has been proven successful,particularly foridentifyingrare
because a biallelic missense mutation in the RAD5/C gene was recently determined tobe
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4.1.13 Common low penetrant variants with increased risk of breast
cancer cases (373),hastwo SNPsin intron 2 (rs2981582 and rsI219648) that. in two
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4.1.14 Syndromicbreasttancer
syndrome associated with an increased risk of breast, thyroid,andendometrial cancers,
4.1.15 Identifying novel breasl cancer mulalions and genes
Approximately 50% of hereditary breast cancer cases remain unsolved. There maybe
othermutalionsineachoftheknowngenesthatconferariskofbreastcancer,however,il
will only be a maneroftime before they are identified by studying other populations,
classifying detected missense variants (UCVs) as pathogenic, and evaluating other
mutation rypessuch as genomic rearrangements and regulatory malfunctions (286).
Despite that many researchers believe in polygenic breasl cancersusceptibil iryandstrive
to pursue association studies that will identify low·moderate risk alJeles (283),therecent
identification of the highly penetrant RAD5/C mutations supports the 'commondisease,
rare allele' hypothesis (289),which indicates that other very rare and highlypenetrant
genes may exist. Anemptstoidentifynewhighlypenetranthereditarybreastcancer
genes have, however, been relatively unsuccessful. There have been severalgenome·
wide linkage scans performed on multiple non·BRCAJ/2 breast cancer fami1ies(376·
379). Huuskoeta/.sludiednon·BRCAJl2Finnishfamiliesandfound linkage at marker
D2SS2262(2q32)(378),andBergmanetal.studiednon.BRCAJl2Swedishfamiliesand
reponedlinkageatlOq23.32-q25.2,12q14-q2Iand19p13.3-q12(376).Anotherstudy
wasperfonnedbytheBreastCancerLinkageConsortiumusingl49non.BRCAJI2
families, and despite the large number of families used,no significant linkage was found
(379). Gonzalez-NeiraetaJ.morerecentlyidentifiedfivesuggestivelocirelatedto
hereditary breast cancer with moderate linkage values at 2p22.3, 4pl4ql2, 7q21.11-
7q21.3,llqI3.5-llqI4.3andl4q21.1-14q21.3(377).Nocausalivegeneshavebeen
suggested to use families from a homogeneous population to reduce genetic variatian
(377). It is possible thaI other homogeneous populations have foundermutationsin
known or yet undiscovered breast cancer genes; and the new,nexl-generation sequencing
tcchnology may ease their identification. Hereditary breast cancer has not been srudi00 in
4.1.16 Aims of this study
The goal of this study was to evaluate, for the first time, familial breaslcancercasesin
identify families suitable for novel gene discovery in breast cancer
This project was approved by the Human InvestigationComminee, Faculty of Medicine,
bloodsamplewastakenfromtheprobandandusedtoextractDNAand,insomecases,
establish a cell-line. The proband's family history was also recorded and the family was
categorized as high-risk (four or more cases in the family) or moderate-risk (two to three
cases in the family). A total of 153 probands were recruited into the srudy, 75 ofwhom
were from high-risk families and 78 from moderate-risk families (fable 4.1)
The project was divided into fWO phases (Figure 4.1). Phase I was completed in Seanle,
Washington by Dr. Terry-Lynn Young, and the results of this phase are presented in
Appendix 10. lnPhasel,thefirst96recruitedprobands(45high-riskfamiliesand51
moderate-risk families) had fuJI gene screening for the detection of point mutations in
only breast cancer cases (23 high-risk,40 moderate-risk) and 33 families had cases of
phase I (Table 4.1 and FiglJre4.l). Thirty-six: of those families had breast caneereases
ovari8J1,cance,·(13 high-risk, 8ffio<lerate-risk). Five of the 57 families had at least one
(i)Proteiotruocatiootest(PT1)
In brief,PTTinvolvesan in vitro transcription mechanism and proteinsynthesisthat
enables the detection ofnuncated proteins. Specially designed PTT primers are usedto
amplify DNA and the resulting amplified DNA products are then used for in vitro
transcription and translation to generate the protein that would be synthesized in vivo.
These protein products are then analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Normal protein products show a particular panemon the
gel whereas truncated proteins from mutated genes are shoner, nm faster and have a
different panem from that ofa nonnal protein (380, 381)
PTT was performed by first arnplifying exon II ofBRCAI, and exons 10 and II of
BRCA2 from genomic DNA. A standard IX PCRreaction cocktail without betaine was
used for all primer sets (Appendix I). AJI amplifications consisted of 35 cycles.Each
cycle had a 94°C 30 seconddenaturingperiod,a 30 second annealing period atprimer
specific temperatures, and a 72°C extension period at primer specific times.Theprimer
sets and amplification conditions that were used had been previously determined in the
laboratory of Dr. Mary-Claire King at the University of Washington (Appendixll)
The Promega TN1"*T7 Quick kit was used to couple the transcription and translation
reaction. Asinglereactionincluded,IO).1I(onefourththerecommendedamount) of TNT
Quick Master mix, 1).11 ofe5S]methionine, and 1.5 J.11 of the PCR-generated DNA
template,foratotalvolumeofI2.5J.1I.Thereactionmixturewasincubatedat30°C for
90 minutes. After incubation. 2 IJlofthe translated sample was added to 20 IJlof6X
loading buffer (the remaining translated sample was stored at-80°C). The 22 IJlmixture
SDS-polyacrylamidegel until the bromophenol blue dye reached the bonomof the gel
After the electrophoresis. the gel was fIXed for 30 minutes in a solution of 50010 methanol,
10010 glacial acetic acid, and 40010 H20. After fixation. the gel was soaked in an aqueous
cracking. The gel was then dried on Whatmanlll 3MM filter paper at 80°C for 30 to 90
minutes under a vacuum seal. ItwasthenexposedonKodakX-OMAT®ARfilmupto6
days, depending on the desired band intensity.
(ii) Single-strand conformation polymorpbism (SSCP)
SSCP takes advantage of the properties of single stranded DNA (ssDNA) during
electrophoresis. Afterdenaturation,ssDNAundergoes3-dimensionalfoldingand,based
on its DNA sequence, may assume a distinct conformation. The conformational
migrate differently on an electrophoresis gel,even though the numberofnucleotides(and
molecular weight) is the same. Thus, a single nucleotide change can be detectedusing
this approach. However, not all sequence changes aredetected,which decreases its
All PCR products that were screened by SSCP were amplified using primer sets and
amplification conditions that were also determined in the King laboratory (Appendix 12
and 13). A l2p dCTP-labeled PCR was carried out. A IX master mix included: 2.5 ~l of
lOX PCR Buffer, 2.5 ~I ofdNTPs (2 mM)(with 5% of the normal concentration of
dCTP), 0.75 ~I of MgCI, (50mM), 0.2 ~1 ofTaq DNA polymerase, 15.85 ~I of H20, I ~I
of the forward primer, I ~l of the reverse primer, and 0.2 ~I Of l2p dCTP. Touchdown
PCRsweregenerallyusedtoamplifythedesiredproduct(Appendix2).
The SSCP analyses were performed using4~1 Of l2p dCTP-labeled PCRproduct and the
sameamountofdenaturingsolmion(95%formamide,20mMEDTA(pH8.0),andO.5
mglml bromophenol blue) for each sample. Samples were heated at 98°C for 10 minutes
and immediately chilled on ice. The DNA strands were separated byelectrophoresisina
non-denaturingpolyacrylamide gel (10% acrylamide) at IOOY for 16 hours at 25°C.
(iii) Automated Cycle Sequencing
The sequencing primers sets were the same as the primerselS used forSSCP (Appendix
12 and 13). A standard IX PCR reaction cocktail without betaine was used for all primer
selS(Appendixl). Touchdown PCRswere used to amplify the desired product
(Appendix 2). The desired PCR products were purifted and prepared forsequencing
following the procedure described in Chapter 2. section 2.2.3(i)
microsatellite markers surrounding the desired locus in order 10 determine ifthey shared a
commonhaplotype,andthusacommonancestor. Six markers flanking the BRCA210cus
were genOlYpe<!; D13S1242, Dl3S1299, Dl3S1287, D13S260, D13S17J, and D13S220
(Appendix 14). A standardPCRcocktail without betaine was used (Appendix I). The
PCR products were amplified using a general cycling program with a 50°C annealing
temperarure (all steps were 30 seconds in duration). Genotypingwas performed by
4.2.4 Screening for BRCAI aod BRCA2 copy number variants (genomic
duplicatioos aod deletions)
(i) Amplification across the breakpoints of known variants
Targeted mutation screening can be performed on known copy number variants when
PCR-based applications have been developed to amplify across the specificbreakpoints
(ii) a duplication of exon 13 (384), (iii) a deletion ofexons 14-20(385),(iv) a deletion of
exon 20 (386), (v) a deletion ofexons 20-22 (354), and (vi) a deletion of exon 22 (387)
For infonnation on each primer set and amplification conditions see Appendicesl,2and
15.Onlyprobandsrecruitedinphase2werescreenedusingthismethod.
(ii) Multiplex ligation-dependent probe amplification (MLPA)
Copy number variants in BRCAJ and BRCA2 can also be detected by MLPA. MLPA
probes mixes POO2 and P045 have been used for the detection of copy number variants in
BRCAJ and BRCA2,respectively. Onlyprobands recruited in phase 2 were screened
using this method. The MLPA step--by·stepprotocol for DNA detectionlquantification is
4.2.5 CHIa c.11OOdelC screening
All 153 probandswere screened for the CHK2 variant c.llOOdeIC. Sincepseudogenes
are present in the CHK2 locus, a nested PCRwas created to increase specificity and
amplify the desired CHK2 fragment. The external and internal primer sets and
amplification conditions can be seen in Appendix 16. The initial PCRusingtheexternal
primer set involved a standard PCR cocktail without betaine (Appendix I). ThePCR
products were amplified using aTD 60 cycling program. A H20 control was used in this
without betaine, but instead of genomic DNA as the template, the PCR product was used
(Appendix I). This PCR was carried out using the TD SO cycling program. ThePCR
product of the H20 control was carried over to the nested PCR as well to ensure there
forthisexperimentwasl24bp. After digestion the wild-type allele was cut two times to
give three bands (74 bp, 31 bp,and 19bp),and the mutant allele was cut only one time to
givetwodifferentbands(93bp,and3Ibp).Thedigestreaclionmixturecontained51.11
of the nested peR produc~ 21'1 of lOX Buffer 3, 0.5 ~l ofBsrl (5U/41) and 12.5 ~l of
probe in this kit was designed such that amplification would occur only when aONA
sample contained the CHKlc.llOOdeIC mutation. Only probands recruited in phase 2
4.3.1 Phase 1 - BRCAl and BRCAl full gene screening
4.3.2 Phase2-Targetedmutationscreeninginnewlyrecruited
probands
Fifty-seven probands that were recruited after phase I had targeted mutation screening for
(i) Positive screen forBRCA2c.6714delACAA-founder mutation
Only one of the 57 probands screened positive fora known mutation. Thatprobandhad
theBRCA2mutationc.6714deIACAA(Figure4.2).BRCA2c.6714deIACAAwasfl.J'St
detected (phase I) in the proband of Family 199. The proband was female and was
diagnosed with breast cancer at the age of 59. There were three total cases 0 [breast
cancer in that family, all of which were diagnosed over the age of SO in females. There
IO,TableAIO.I). The newly recruited proband that screened positive forBRCA2
c.6714delACAAwas from Family 1191. The proband was female and diagnosed with
breast cancer at 37 years of age. She also had a secondary ovarian cancer. The sister of
the proband was also diagnosed with breast cancer under the age of 50. Theprobandhad
two brothers diagnosed with cancer, one brother had throat cancer and the other had
4.3.3 Screening for BRCAl and BRCAl copy number variants
were too low to make reliable calls. Of the 57 probands screened by MLPA, 43 and 39
weresuccessfullyscreenedforBRCAJandBRCA2,respectively.Novariantswere
detected in any of those probands, and the positive controls worked well each time
4.3.4 CHlil c.1l00de1C targeted screening
All 153 probands from phase I and 2 were screened for the CHK2 c.llOOdelC mutation
(Figure 4.1). This mutation was found in 2% of the probands studied (3/l53) (Table 4.2
and Figure 4.6). Two of the probands were from phase I and one was from phase 2. All
three probands were female and their primary cancer was in fact breast cancer. All were
52 years of age at disease onset. Two of the three probands had a second primary cancer,
one had multipiemyeloma and the other had ovarian cancer. Therewereatotalofseven
Only one family showed instances of ovarian cancer. All three families had other cancers

Since genetic isolates have been established in the ewfoundland population, and founder
(87,9l,97,l09,390),itwasdecidedtotakeatargetedmutationscreeningapproachafter
phase I and screen all newly recruited probands for the BRCAJI2Newfoundland
mutations to determine if there were any founder mutations inthepopulation (phase 2)
Only one of the 57 new probands screened positive. BRCA2 c.6714delACAA,was
detected ina second family and an ancestral haplotype appeared to be shared by the
probands.Therefore,itislikelyafoundermutation.UnlikethisNewfoundland cohort,
somepopulationsaroundtheworld,likeRussia,haveahighpercentageofBRCAland
very beneficial (389). The unsolved probands from phase 2 thereforeneedscreeningof
the remaining unscreened exons ofBRCAJ and BRCA2 in order to exclude these genes as
pathogenic, and identify families for novel gene discovery. Despile the low detection rate
harm in first screening the exons with known mutations, followed by the screeningofthe
remainingexons.ThisapproachmaysolveonlyasmaUnumberoffamiliesbutoverall
will save lab funds if there isapositivescreen-the main purpose of targeted mulalion
Newfoundland'sancestrycanbetracedbacktoEnglandandlreland(86,87),and 13 of
all have a westem European ancestry (eight specifically mention Britain or Ireland). Of
Dutchpopulation(392),andc.4642delAAGA,toourknowledge,hasnot been reported
before. This mutation may have occurred more recently, perhaps since the family
migratedtoNewfoundland.lnteresting.theBRCAlmutation,c.4446c>T,isawell-
is actually a smaU subsetofa larger family with mainland Canadian ancestry therefore
this mutation may be the same founder mutation as observed in French Canadians.
screened positive for the CHK2c.llOOdeIC mutation. This allele is estimated to increase
breast cancer risk by two-fold and account for 1% of all breast cancers (357). It also
accounts for approximately 2% of the 153 probands in this studywith a family history of
breast/ovarian cancer. Despite that CHK2 c.1 100deiC mutation carriers generally have an
earlyageofbreastcanceronset(357),thethreeprobandsthatscreenedpositiveforthe
CHK2 variant in this study were all diagnosed at the age of 52 years. All threeprobands
also had first degree relatives with breast cancer, all of which were diagnosed over 50
years of age. Segregation of the CHK2c.llOOdeIC mutation within these three families
wasnotperfonnedbecausetheDNAofadditionalfamilymemberswasnotavailablefor
Of the 96 families that had full gene screening, 84.4% were BRCAJ and BRCA2 negalive
(mystery families). However, point mutations in these families may have gone
undetected since the sensitivity of the detection methods (pTIand SSCP) was notlOOOIo
If DNA from multiple affected family members is available, linkage exclusion can be
perfonnedto rule out BRCAJ and BRCA2 involvement. Otherwise, genomic
rearrangements have to be considered, as well as, deleterious variants in promoter
regions,UTRsand intronic DNA. Many of these families have distinct characteristics
early age of onset., bilateral breast cancer, multiple cases of breast cancer, one or more
family member with two primary cancers, etc. (336,393-395). lt is likely that the breast
could low~moderate penetrant genes or novel high-penetrant genes (BRCA3) be causing
Previousanemptstoidentifynewhighly-penetranthereditarybreastcancer genes have
been relatively unsuccessful; several genome-wide linkage scans were perfonnedon
multiple non-BRCAJI2 breast cancer families to no avail (376-379). More recently,
identifyingcommonlow~penetrantallelesthroughgenome-wideassociationsrudieshave

Table 4.1: Proband categorization into study pbase, bigb-or moderate--riskfamily,
and age of onset.
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Figure 4.4: Positive controls rorfouroftheBRCAl genomicrearrangements
screeoedby PCRandgel electropboresis.
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ChapterS: General discussion
(126) to diagnose ARVC in this study was difficult because the historic nature of the
Newfoundland ARVC pedigrees (clinical details were not available for many individuals
in earlier generations and SCDwas the primary disease feature), and presently thereisa
lack of availability of clinical tertiary care centers in the areas of the province where most
afTectionstatus, which overcame diagnostic difficulties that may have hinderedprevious
genediscoveryefTons. Crucial for the gene discovery was the recruinnentofthe
Identifying key recombinations in two of these families reduced the critical regiontoa
reasonable size for positional cloning and ultimately led to the identificationofTMEM43
as the causative gene. Furthennore, with the overall goal in gene discovery beingthe
improvement of disease management, it is an honour to report that this gene discovery
has enabled a clinical diagnostic test to be designed and offered to aHiskfamily
members. Due to the serious repercussions ofARVC, this gene discovery will aidin
early diagnosis and the implementation of the proper preventative measures that will save
lives, including the use of implantable cardioverter-defibrillators.Assuch,therearealso
potenlial impacts on public health policy considering that the TMEM43 founder mutation
raises issues regarding the best way to provide genetic health care (mutationtesting,
genetic counseling, and follow-up specialist interventions).
The X-linked deafness family studied in Chapter 3 represented another large and
eXlendedNewfoundlanddiseasepedigreethatappearedtohavethepotentialtolocalizea
of this pedigree lhe proper medical records were not always available to diagnoselhe
disease, especially in lhe earlier generations. Medical records were only available for 15
of the 50 reported affected individuals and therefore, disease status was mainly
detennined by a clinical history as recollected by relatives. Large pedigree size andthe
large number of apparently affected individuals can theoretically facilitate the
records, the most likely mode of inheritance of hearing loss in Family2024wasX·linked
male·maletransmission. Newfoundland represents a population of out·migration which
affected individuals. HaplotypesspanningtheentireXchromosomerevealed only one
region that was shared by all afTected individuals that participated in the genetics study· a
13.3 Mb region on Xp. Of interest was a 0.96 Mb region of homozygosity in a woman
with two related,affected parents. That region of homozygosity could have potentially
reduced the disease region to the DMDlocus; a higher participation ratecouIdhave
confirmedthis.Overall,nopathogenicsequencingvariantwasdetectedaftersequencing
positional candidates in the 13.3 Mb region, unlike the detection ofTMEM43c.1073C>T
(p.S358L) in ourARVC cohort. However, in this case only the coding regionsofcochlea
expressed genes were sequenced, whereas in the ARVC study aU coding and non--coding
exonsofall positional candidates were screened. Thus, the variant could be in a gene not
yet screened,in a non·coding region ofa gene that was screened, within an unidentified
isofonn or gene within the critical region, or it may even be a copy number variant.NGS
will probably be the next best approach to solve this family. A target-capture of the 13.3
Mbdisease region can be perfonned and the region sequenced,which will identify both
coding and non--codingvariants, and potentially even rearrangements. Or a cheaper
option would be to perfonn an exome capture and sequence basically aU codingexons in
the genome. Using this approach one would hope that the variant is coding (orin an
intronic region that is close to an exon) but it would be beneficial if the mode of
Lastly, the Newfoundland population provides an opportunity to identify a novel breast
cancergene(s).Conventional,full-genescreeningin96Newfoundland breast cancer
probandswithafamilyhistoryofbreastcancerident'ifiedl5BRCAIandBRCA2
an additional two of the 96 probands later screened positive for CHK2 c.IIOOdeiCand
BRCA2 families with yet-unidentified mutations, there remains an opportunity for novel
gene discovery. Previous attempts to identify new highly penetrant hereditary breast
cancer genes in non·BRCA1/2 families have been relatively unSllccessful(376-379),
beneficial would be to study families from the same genetic isolate. Acommon founder
mutation may be uncovered. The remaining Newfoundland mystery families providean
opportunity to find a highly sought after, novel breast cancer gene. ExtendedfamiIy
members are being recruited from the most infonnative mystery families, and the
island. Mystery families that originate from the same fishing communities may represent
to identify low-moderatepenetrance breast cancer alleles as well
Overall,it is beneficial to study isolated populations like Newfoundlandwhenmaking
gene discovery efforts. It takes luck and hard work to find the ultimate,adisease gene. I
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Appendixl
The lnvitrogen'IM Taq DNA Polymerase kit (Cat. #: J0342020) was used for the
Appendix 2
Touchdown (fD) peR
Touchdown PCR is a W8ytO increase specificity. The stringency of primer hybridization
spurious products are not favored to anneal and the desired product is predominantly
amplified. Therefore, the annealing temperature is first set above the expected Trn and
Anexampleofatypicaltouchdowncyc1eisTD54.Thereare5initialtouchdowncycles.
The first cycle has an annealingtemperarure 8"C above (62"C) the desired annealing
temperature (54°C). Then in each additional touchdown cycle the annealingtemperature
decreases by two degrees until it reaches 54°C, The PCR then continues for an additional
30 cycles at annealing temperature 54°C in order to get the desired amountofproduct.
All steps (denaturation, annealing and extension) are 30 seconds long.
Appendix 3
ARVD5 positional genes-primers and ampUfic8tion conditions
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Appendix 4
MutatiooSurveyor
Mutation Surveyor is advanced software for analyzing sequencing data. which compares
your sequences to a reference sequence and aids in mutation detection. TheMutation
Surveyormanuai can be used to understand the program. in additjon, stated beJoware
(hllp:" .ncbi.nlm.nih.govD.Underthesearchoptionsgoto'CoreNucleotide',then
type in the accession number of the gene of interest, and press 'Go'. Oncethesearch
results appear, click once on the 'Links'tabthat is directly to the right of the desired
accession number. A Iislofseveral options will appear, select 'Map Viewer'. Oncein
Map Yiewer look on the right hand side of the page just below 'Maps and Options',
'Oownload/ViewSequencelEvidence' should be an option, click on the
'Down!oadIViewSequencelEvidence'link.Herechangethe"Strand"to plus or negative
depending on the gene of interest, then click 'Change RegionlStrand'.Also,changethe
'Sequence Format'toGenBank. On the same page under the 'This chromosome region
corresponds to the contig region(s)' section click 'Display'. That will display a report for
the genomic area of interest (which contains your gene of interest). In the 'Features'
section, three options should be checked (STS, tRNA and microRNA). The only option
folder as a text file under encoding 'Unicode (UTF·S)'. Forsimplicity,the name of the
Analyzing sequences ofa particular gene in Mutation Surveyor for the first time requires
to first save the downloaded reference sequence text file (described above) as a GenBank:
'·.gbk' file. The most efficient way to do so is to open Mutation Surveyor, click on
'Tools',then'GBKfileeditor.. .'.OncetheGBKfileeditorisopen,openthedesired
text file by either clicking on 'Open' at the bottom of the editor page orclicking'File' in
thetoolbar, then 'Open'. Once the folder in which your text file is saved in isopen,in
order to see your text file you may have to change the File type to Text (•.txt) because the
defauh sening is GenBank file (·.gbk). Once the file is open there should be four tabs
acrossthetopofthepage,General&Reference,Featuresl,Features2,andSequence
select your gene of interest because the default setting selects the first gene in contig to be
analyzed. Once your gene of interest is selected make sure the proper proteinsequenceis
recorded,thenclick 'Save As' at the bottom of the page. This will convert your text file
to a Genbank (gbk) file. Save the file into the same folder as the text file . Remember the
sequences of that particular gene. Close the 'GBK file editor'
In order to analyze sequences click on 'File' then 'Open Fiies'. By clicking ,Add'inthe
'GenBankSequence Fiie(Optional)' section you can upload your referenee (gbk) file.
Then add your raw sequencing data to the 'Sample File' section by clicking 'Add'and
locating the raw sequencing data. Both forward and reverse sequences can be added to
this section. Press'OK'onceeverythingisup)oaded. Go to 'Process' and click 'Run'.lf
forward and reverse sequences are added together then they will be divided intodifferent
contigs.Atableofthevariantsdetectedineachsampleisshown.Formoreinfonnation
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Appendix 6
Panel 28 oftbe ABI PRISM Linkage Mapping Set (v2.S-MDIO kit)
Appendix 7
X chromosome fine mapping markers
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Appendix 9
Manually designed MLPA probes for non-overlapping DMD exons
DpIl6.ExI=SyntbeticMLPAD·ProbeCbr.Xp21.2
Synthetic MLPA probe for the detection of exon 1of the DMD gene, isofonn Dpll 6
Genbanksequence:NM_004014
Totallengthprobeincl.primers:63+63=126nt
G4;lnomic area around Ex 1 of Dp1l6. Lowercase letters represents
intervenlng:5equences,uppercasesletterrepresentstheexon.Red
letters are non-coding and blue are coding.
GenomicareaaroundExlof0p11.Lowercaselettersrepresents
interveningsequences,uppercasesletterrepresentstheexon.Red
letters are non-coding and blue are coding.
Appendix 10
Phase 1 - BRCAJ and BRCA2 full gene screening results
Ninery-six probandswith hereditary breast cancer from the population of Newfoundland
had full geneBRCAI and BRCA2 screening for the detcction of causative point mutations
the 96 probands, 8 mutations inBRCA/(8.3%)and 7 mutations in BRCA2(7.3%) (Table
AIO.I,and Figure AIO.I and AIO.2). Eleven of those 15 mutations (73.3%) were
identified in high-risk families (7 BRCAI,4 BRCA2) and 4 (26.70/0) were identifiedin
moderale-riskfamilies(IBRCAI,JBRCA2)(T.bleA.IO.2). BRCAlandBRCA2
mutationsexpiain 15.6% of those 96 Newfoundland hereditarybreasl cancer families
Only one of the mutations, BRCA2c.4642deI4, had not been previously reported(332,
388). Anothervariant,BRCA210204A>T,wasdetectedbutconsideredanunclassified
variant(389),therefore, it was not included in the lisl of pathogenic murations.This
variant is in the lastexon (exon 27) of the BRCA2 gene which is nottranslated,thusits
Eight probandsscreened positive fora BRCAI mutation (Table AIO.IandAIO.2).The
average age of diagnosis foraBRCAI proband was 41.8 years. All BRCAI probands
were female. The primary cancer site for six of the eight BRCAI probands was thebreast,
four of which had a second primary cancer (two had a second breast cancer and two were
also diagnosed with a primary ovarian cancer). The remaining two of the eight BRCAI
probands were diagnosed with ovarian cancer only. Seven of the eight BRCAI probands
were from high-risk families and one was from a moderate-risk family (fable A 10.1 and
AI0.2),with an average of nine breast or ovarian cancer cases per BRCAI family. Forty-
age of SO (80.8%). There were IS ovarian cancer cases in the eight families (an average
of approximately two ovarian cancers per family) and one male breast cancer case. All
SevenprobandsscreenedpositiveforaBRCA2mutation(fableAI0.landAI0.2). The
averageageofdiagnosisforaBRCA2probandwas47.9years.Allprobands,butone,
were female. All probands had breast cancer as their primary cancer. Three of the seven
probandsscreened had a second primary cancer in the breast, and one proband had a
primary ovarian cancer as well (Table AIO.I). Fourofthesevenprobandswere from
high-riskfamiliesand3frommoderate-riskfamilies(TableAI0.landAlO.2),andthere
was an average of five breast and ovarian cancer cases per BRCA2 family. There were a
diagnosed under the age of SO. There were three ovarian cancers diagnosed (less than one
case per family) and three male breast cancer cases. FourofthesevenBRCA2 families
'"0<5 fj,
~Jfj,sH~ I;I~hI
TableAJO.2: Categorizationoftbe 15 BRCAI and BRCA2 mutations found inpbase
lintobigb-andmoderate-riskfamHies
FigureAIO.I:DistributionoftbepathogenicmutationsfoundinBRCAlandBRCA2
duringpbase1.
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Appendix 12
BReAl sequencing and SSCP primer sets
1.1A-a1.'" ".lIT.foA.U(:UC&&CCIo51GCMTMlilCOQCMC1l1C1AA~
1.U.tl.. ,...-CAMAAACA8CTA1&f.CCTTCACMOQCC'TTACQCC'1'C-r
1.1-14N'. ·.1'81.UAACllo\al8CCA8~CGTTllTCAnMlncn.:r
1.ltMI1. _CAMA,U,CAacuT&ACCCATllTCTTTTClTCCCTMI1ATO.:r
l.).t_UFr-'RJTAA.Ut~1ATTllAACGMCTT8M184'
1~111.'. r.cAMlMClacu1lilCC4"C1CACTTAATT~.r
1~111II1" _'1SlAA.UtUCMCCAeTA8tTTTTT8CTTATQCAQCA.r
'.502m1IM .a.MLU.allCtl"NlloeCGCATTAQAlOAMGGCAOT.u.GTTTC4
......' ..1••'Ntw.lC"'*ICCAlInoc:a.1CACN»8mATACA.J'
U.l..t.~""'18ACCCCTMlAC1MAAGOTcnATCAOCA"
1.J.'lllItlf'r·TIt.t..toAACMCMCCl8'1CACAACA.U1GMlCATN:JJ,TAllQG.l'
1.7.1.,. ~""'18ACCMM:MCTGCTTC1AOCCTlI.J'
I '...'NUA.UCualKCMTraTTMCTlIAC"NATU'MT.r
I '••a ........aKlI18ACCTTT"CAAMCTATAAGATMaO·,.
' IF .T8T4UACualKCMrrrtllTIICCTOCCACAGTAQATliICTC.7
, ,••CAIIUlAClICU1'6ACCCAMCTOCACATACATCOCTeMt:4
IIF 1.1.... 11IF .16T.I.A.UoC&ACS6CCA6TTGCIlCNilCTTTCTllTMTca¥
lilt 1.11t.'••CA66MACl&CV.lUCCAllaTCCCMAlllllTCTTCtoQ·,.
11M- l.tUl·'_aF .WULUC&AC6&CC.l8TTASCCAGTTGGTTClATTTCC.r
11M 1.1_'. 1'.cJo86AAIoCA6CTA1eM:CcncCAliOCColTCTllTlATll4'
.151A.UAC6IoC6&CC.llllCACMATAClCATGClCA$CT.!J'
"ClMlAACA6CTA1&foCCACCTCAmAQAloCGTCCU.J'
.18TA.UAC&AC6&CC.l6ll;C,WCATTCAlIMA8TTMTaMTlI.f
-CA66UACA6CU1&IlCCTCC8TTTGGTTAGTTCCCTlI-r
_16TA.UAC&AC6&CC.l61lToU.1ACNtaAllCGTOCCCl-r
,'.Cl&6.tMCA6CTAT&ACCGCMTTClGTACMnAGOTGG.f
'.16TA.UAC6IoC66CCA6TQCAlfTATMGCMTATGGAACTCG..r
1'-Cl66A.UCA6CTAT6AWTCmIlGCOTClTCAQCAT-3'
'·T6TA.UAC&lC8&CC.l61QCACCTIIllT1CTTTTACTMlfTGTT.r
'~88AAlClIClA_CCCCTeeATmlAJN.CG8AOC4'
'_TtTJ.UAC&0\C68CCA8lATCCAn8CQACATGAAGn_f
'-CllWlAAAClIClA_CCllAT8CQM.AMGT8QTQQTA~
'.TtTA.UAc:MC68CCA81'GCCAGTTQATAATOCCMATQTAQ4'
1'.QII8AAAClIClAlUCCQGATQCTTACAATTACTTCCAQQA.r
\TaTA.UAc:MC68CCAIlMCATTtM8CAClAACTAQQ.!f
'.a.MAAAClIClA_CCQMQCTCTTCATCCTCACTA~
''NTAAAACMalK:ClllQCAAMQC81CCAClAAAQQA4
caMAAACl6CTATlMCCACTCAGACCMCTCOCTltc.r
IIICF I."'fF .'NTAAAACMal8CCAllAMCATC1CAGOMCATCAC4'
111(1I. ,.111..1,.,_ ~IUAACAICTA"'CCATllNoMClCACcnAee"I.r
.TlUAAACIIoC8ICCAllGTCCTtcCAATllAllAAGAAA4
_CAM.t.MCAlCTAlUCCTQTCAClCAAACCTAA4MTQT4'
IIIF '.'MallllF .TlUAAAClIIoC66CUI81CCATACTAQGlUmWTTCCTN
'M 1.'''111I'••CAM.t.MClICTATW.CC1'ACCCUQTQC1QAGCN11i1N
·.TIITAoUAC6AC66CtA61CTMCCTGMnA1CACTA1CA~
_CAMAAACA&CU.lUCCCTlllAlMA1ClCCflllA10CA.:r
·TIITAoUAC6ACACCA6lTGOCTiCCCMCAMTAl.~
·.CAMUACAacTAlUCCMCCAQAA1AlC'lTlAl.1AGGA~
.TII1A.UACMClMCc.M1MnCTT.u.cAlLWACCIo8AAC~
·.CAMAAACAacTAlUcc.u.MCTC'ITlCCAQM1VTTlIl~
'" 1.I7+1_nF _'NtUoUCMCIllJCCA8lCGlllCAClU.nGCTACA1~
1m 1.1,....1. LIIMoUACMlCTAlUCCCA1GlGOlTllATClCACCA-a'
-= 1.1~'rF TIIUMACu.c.ecCMTtlOCTC'ITl,.cnCTTAaGAC.r
1M 1.1..1,." .CAeuMCAlCUlUCCGAlOAoOCCATTTTCCCAOCAlC.r
IF 1.IMnl,rF .TIIUMACMC6ICUIl'CTlIlCAnCTTCCTGlIilCTC.r
1M 1.1"",,.1. ·CAeuMCAICUlU.CCCAllGnAAClGMAGlGlIlGC.r
_ l.au.lrF .TaUMACu.c.ecCllillA1A1G.llOQTG1CTIilCTCCAC.r
_ I.a.:n... ·CAeuMUlCUlUc:c:GOllM1CCAAAnIil:.ACAGC-a'
:nF 12~I_'rF _lnUUCMCMCCAeTIICMlCAGMA1CA1CMlG'T8-a'
:nRI21t:n1... ~MC'D.lUCCATGCTCTTGMM.GGOGUC.r
.TIITAoUACMaMICCMli ___
CAMAAACAlCUlU-.o__
_TIITAoUAC6IIC&eCc.MTAG~CTc::c:cAT'lGJ.G4'
ZlR lno......CA.........CAKTAlWletAA1CCTTAoOOCATCCCl'TAC..s"
.,.T.OA.U<M<&OC<.O__........,GlCTC~
U .........CAKTAlUCCACTGTGClACTCAAGCACCA ...
• TIITAoUACUCACc.MTATsunQAC,ACTIiATCTCTClC.r
.CAMAAACAacTAlUcaTAGCCAGMCAllTAGAAGGIo.r
Appendix 13
BRCAl sequencing and SSCP primer sets
hon P~... NI.' Pri..,
l~ 8U-1201113F S··TGTU....CGACGGCCAGTT1CCAGGAGATGGGACTGUTTAG .,'
l~ BU'UlllS~ S'.CAGGUACAliCUTG.l.CCAAGCMCACTGTGACGTACTGGG·'
SF BU·1ZS1II13F S'.TGTUUCGACGGCCAGTGCClTAACAMAGTAATCCATAGTC-3
SR BU.,0UllJ1l $'.cAGG.l.UC.l.GCTATG.l.CCGAGAGACTGATTTOCCCAG.'
H BU·IIUllSF S'·lGTUUCGACGGCCAGT'TCTCATTCCCAGTAlAGAGGAGAC·!
II{ BU+nUI13R S'.CJ,GG.l.UCAGCUTGACCCAGtC.v.TTCAACATCACMG·'
UF BU.I·234M13F S·.TGT.u.u.CGACGGCCAGTTACACGGTTTCCAGCAGC~
UR8U.I'\0311URS'.c.l.GGAUCAGCTATGACCOCAGMTGCTAGGTACAGATTTGTA·'
IF 8U·1311113F S'·TGTU.u.CG.l.CGGCC.l.GTTCTG1ACCTAGCATTCTGCC·'
IR 12.1+1G31113f S'.(.I.GGU.lC.l.GCTATG.l.CCGACACCAC1GGACTACCACT.'
IF B2.WIlIII!'F S'.TGTUUCGACGGCCAGTCC,v,CTCATTGTGGACJ.GTA.,
'R 8U+')Ull)l1 S·oC.l.GGAUC.l.GCT.l.TG.l.CCCC.l.GGTTT.l.G.l.G.l.CTTTCTCA~'
" BU.22)1I13F S'.rnTUUCG.l.CGG<:C.l.GTCCACATCCT.l.GTGGTGCA.l.G.l.TTTC·3'
'II BU+10l111131l S'·CAGGU.l.C.l.GCT.l.TG.l.CCCIOGT.I..I..I.CTGAG.l.TC.l.CGGGTG.'
l00'.1B2,lI).1I411'" S'·TGTU.I..I.CG.l.CGGCC.l.GTGCTTT.l.CT.l.G.I..I.G.I..I.C.l.GG.l.G.I..I.GG·,
IO.I.RB2.1U2111SJ1. S'oC.l.GGA.I..I.C.l.GCT.l.TG.l.CCGG.l.TC.l.GT.l.TC.l.TTTGGTTCCAC·'
lOB1B2.1121I1Uf S'.TGTUllCG.l.CGGCC.l.GTG.l.T.l.CCTCTGMGAAGAT.l.GTT.,
10BRB2.'.1111J11. S'oC.l.GGA.I..I.C.l.GCT.l.TG.l.CCGTATG.l.G.l.TTCAAGATGCTG·'
lOG1 B2.14rCII13F S'.TGTU.I..I.CG.l.CGGCC.l.GTGCATAmCTTCATGTG.l.CCA·'
lOCRB2.1.11111311 S'oCAGGA.I..I.CAGCT.l.TG.l.CCGCCAGCTTCCATT.l.TCAATTA.s
1001B2,17&11I13f S'·TGTUllCG.l.CGGCC.l.GT.I..I.G.l.GACTTTC.I..I.TGCAAGT·'
l00R BVl1SMI'R S'.cAGGAUC.l.GCTATG.l.CCTTTGAGTG.l.CCTGATTCTAA ~
l'A1B2.11A·I5I1'''' s'·rnUU.l.CG.l.CGGCC.l.GTTGTGCCCAA.l.CACTACCTTT.s
llAR B2,2S52111'R S'·CAGGAUCAGCT.l.TGACCG.I..I.GT.l.GGAGTTA.u.AT.I..I.GAGTGC·'
s'.rnTUUCGACGG<:C.l.GTGGACAGTGTGAA.u.TGATCC·3
S'.C.l.GG.l.UC.l.GCT.l.TGACCTGAG.I..I..I..I.GTTCTTCAGAGTCTG.s
s'·rnTUuCG.l.CGG<:C.l.GTTTGAGCTGTTGCCACCTGA.s
S'·C.l.GGAUCAGCTATG.l.CCGCCCATTTGTTCATGT.I..I.TCAT·,'
S'·TGTUUCG.l.CGGCC.l.GTGGTTTT.l.T.l.TGGAG.l.C.l.C.l.GG~
S'oCAGGAllC.l.GCUTG.l.CCTGGAA.u.UAC.l.TCTG.l.GGG.s
S'·TGTullCG.l.CGG<:C.l.GTCMAAGAAACTGAGCUGCC.,
S'·C.l.GGUACAGCT.l.TO.l.CCTTGTGCC.l.TGAGCAG.I..I.TU·S'
S'·TOTUUCG.l.CGGCCAGT.l.TT.I..I..I.CGG.I..I.GTTTGCTGG·'
S'.CAGGAUCAGCT.l.TO.I.CCCACTGCC.l.TCMATTCTAAG.s
S'·TGT.l.U.l.CG.l.CGGCCAGTGCAGAGGTACATCCAAT.I..I.G-3
S'.cAGGU.l.CAGCUTG.l.CCGACTCmGGCGACACTuT·3'
S'·TOTuUCG.l.CGOCC.l.GTGCTCAAG.I..I.OCATGTCATGG.S
S'·CAGOUACAGCT.l.TO.I.CCGGCT.I..I..I..I.CTGGTG.l.TTTC.l.CT-3
S'·TOUuACG.l.CGOCC.l.GTGTTGGGTTTTCAUCAGCU-3
S'·C.l.GGUACAGCT.l.TO.l.CCGTCTOACTCACAG.I..I.GTTTTTCT.l.C·'
S'·TOTuuCG.l.CGOCC.l.GTCAGCAUMGTCCTGCMCT·'
S'·CAGOUACAGCT.l.TO.l.CCTCCTCMCGCMATATCTTC·3'
S'·TGTUUCG.l.CGOCC.l.GTTGAGCCAOTATTGAAOMTGTTO.s'
S'·C.l.GGUAC.l.GCT.l.TG.l.CCCTCCAATCCAG.l.CAT.l.TTTTGG~
S'.1GTUUCGACGGCCAGTCGMMTTATGGCAGGTTGT·3'
S'·CAOGAUCAOCTATGACCCTGTACTMATCCAGAGMAGCAGA.)
" .. F8Z.I2,3.. ,Y S'·1GTUUCGACGGCCAGTCGCUGACUGTGTTTTCTG·3
11.. R82.S5SI .. '3R S'.CAGGUACAGCTATGACCCCAmCTGAGTTTACACAGTG·$
l1h'F82.S"II"'Y S'.1GTUUCGACGGCCAGTGGGAGTGTTAGAGGMTTTG.)
l1h'R8UIUllI31l S'·CAGGAUCAGCUTGACCGCAGTTTAGAATC1GTCAGTTC.:r
110FIZ.1U1UIII$FS'·TGTUMCGACGGCCAGTGGMMGAACAGGCTTCACCTA·$
110R8Z.11+IU$1I1)RS'.(:AGG.UACAGC1A1GACc.ATCAAACCATACTCCCCCM.)
lZF 82.12·2211113F S'.TGTUUCGACGGCCAGTGACCC1GTTW1AG1GGTGT·$
lZR8Z.12t\32I1URS'.(:AGGAUCAGCU1GACCTCCTTGAlTAGGCACAGTG·3
l$F BZ.l,,13QlIl$F S'·101UUCGACGGCCAOTTATTGAGCATCCGTTACATTCACTG.3
"R S'.CAGGUACAGCUTGACCACCACCAMGGGGGAWCC·:r
lW IZ.l"·1121113F S'·10UAUCGACGGCCAOTGAGGTAGAlTGTWG1CAMGGCT.)
lURU.15.ullI3R S'..cAGGAUCAOCU10ACCCATGTCCATCAATGTTTTGC·)
'''8FIZ.1oIQU.'3F S'·TGTAAUCGACGGCCAGTGACACTTGATTACTACAGGC·$
U8R8Z.1"+Z3I1I1SRS'.(:AGGAUCAGCTATGACCGTAACAGCAGTCCTAGATTG·3
15F 8Z.15-1131113F S'·1G1UUCOACGGCCA01GAGACAGGGTT1CTCCATTT1GG.)
ISR82.1klltllURS'·CAGGAUCAGCTATGACCCATCCATTCCTGCACTAATGTGTTC·)
llF 'Z.If-2oelll)F S'·1GlAUACGACGGCCAG1CAGCAGACTGTGGAATGTATGGATC·'
I1R S'·CAGGAUCAGCTATGACCTAGCUTCCCCAMTAGTG-3
l1F 82.11.201111)F S'·1GTUUCGACGGCCAGTCACCATGCTCAGCMTGMGT·3
liR S'.CAGGUACAGCTATGACCMGCTCMGAUGATCTCTGGAC·'
lW 82.1"232I113F S'.1GTU.u.CGACGGCCAGTATCCACTATTTGGGGATTGC·t
lURBUUB.. ISR S'.(:AGGAUCAGC1ATGACCGAGGGGAGGATCT.u.CTGGGS
U8FBUUllll,F S'·1GTU.u.CGACGGCCAGTGATAGMGCAGUGATCGGC-S
'''R B2.'''''''''UR S'-CAGG.U.ACAGC1A1GACCCAG1ACATCTUGWTTGAGCATc.3
liF 82., .. ,UII'3F S'.1GTUUCGACGGCCAGTTTTACTG1CTTAC1M1CTTCC.)
l1R82.1""D1I1URS'-CAGGAUCAGClA1GACCTCTCCATCCAC1GTAATMT·)'
ZDF 82.2ll-BII.II'F S'·TG1UUCGACGGCCAG1GCCTGATACMTTUCTTGUTG·)'
21R S'·CAGOAUCAGCTATGACCGCAGCATlTCMCATACTCCTTCC.)
21F 82.21..21.1"F S'·1G1UMCGACGOCCAGTGGTGTTTTA1GCTTGGTTC·3
ZIR8Z.Z1.20Slll3RS'-CAGG.U.ACAGC1A1GJ,CCCTCCCA1CCTC1ACTCGGT-3
22F 82.22·2D51.11)F S'.1G1UUCOACGGCCAGTGAGGATCATTTTTGCCG1AGGG.)
22R S'·CAGGAUCAOCTATGACCGCCAACTGGTAGCTCCAACTUTC.)'
23F BU).I'2IollSFS'.10TUUCGACGOCCAOTATCAGAGUGCAAUTCCAC-S
23R B2,2Stl11I.1URS'.(:AGGAAACAGC".1GACCCGACAMTCCTATTAGG1CC·3
HF BU40"""FS'·10TU.u.CGACGGCCAOTCATACAGlTAGCAOCOACAA.)
24R 82.2hl"'lllSRS'·CAOG.U.ACAGCTA10ACCGAGliTTCAUGAGliClTAClT..s
UF 82,25-1UI.I13F S'.1GTUUCOACOGCCAOTOTCATTTTGGAMACC10AOCTTTC·'
UR82.Z5+IISll13RS'·CAOOUACAOCTATOACCCATTCCCCCATCTCCTGAOO.)'
21F n.zt.2QaY1SF S'·TOTUUCOACOGCCA01CTCTCCCTATCAOCTAGATTCCCC·3
21R n.ze+,UliI13R S'·CAOOUACAOCTATOACCcTTACAGGAGCCACATUCMCCAC·3
21AF n.27A·1U.. ,SF 5'· TOTUUCOACOGCCAGllCtlll11nlt'lIU~~ln.)
211.11 U .271..'112 1.1 I3Il 5', CAGOUACAGC TA TGICCI.~Ullltc""III~1lIIU .f
21BF8U78·2521.11SFS',10TUUCGACOOCCAGTCCUGGAGTTGTGOCACCM.)
218RIU1B.l,,,,3I1S'-CAGGAUCAGC,,,1GACCACGGMTCGGGCAMACGAT·$
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Appendix 16
~~r-'~>CR t - ll:J""~IGTCTMATGGACGAGTGGGCTG WCAGMACAJGAACTTCAGGCG60 '05',
tntll'Tllll TGATCTAGCCTACGTGTCTTCTTGG TCTIGGAGTGCCCAMACCA 50 124b
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